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ABSTRACT
REGULATION OF THE CATALYTIC AND ALLOSTERIC 
PROPERTIES OF PHOTORECEPTOR PHOSPHODIESTERASE (PDE6) 
BY THE GLUTAMIC ACID-RICH PROTEIN-2 (GARP2)
by
Wei Yao
University of New Hampshire, September, 2013
The photoreceptor phosphodiesterase (PDE6) must be precisely regulated to 
control the sensitivity, amplitude, and kinetics of the photoresponse during excitation, 
termination and adaptation to light stimulation in rod and cone photoreceptors. The 
central hypothesis of this thesis is that one PDE6 binding partner, the glutamic acid-rich 
protein (GARP2), may regulate PDE6 to reduce its “dark noise”, enhance its sensitivity 
and conserve metabolic energy during rod photoresponse saturation.
The first aim of this research is to better understand the unique biochemical and 
biophysical characteristics of GARP2 in order to reveal its functional attributes for 
regulating PDE6 during phototransduction in rod photoreceptors. We first improved 
immunological methods to better characterize GARP2. We then developed approaches to 
purify PDE6 free of GARP2; we also generated recombinant GARP2 to permit study of
its biochemical and biophysical properties, and discovered that recombinant GARP2 
suppresses the basal activity of PDE6, and behaves as a natively unfolded protein in 
solution.
The second aim is to identify the interacting sites between GARP2 and PDE6 and 
determine the regulatory mechanism of GARP2 on PDE6 in visual phototransduction.
We demonstrated that the N-terminal half of the inhibitory y subunit of PDE6 (Py), 
interacts with high affinity for GARP2. The C-terminal portion of GARP2 is most 
effective in suppressing the basal activity of PDE6, whereas the central region of GARP2 
reduces cGMP binding to PDE6 GAF domains. This suggests that GARP2 alters both the 
allosteric and catalytic properties of PDE6 to regulate PDE6 activity and lifetime through 
multiple interacting sites with the PDE6 holoenzyme. GARP2 may play an important role 
in lowering the level of dark noise, and reducing cGMP metabolic flux during rod 
photoresponse saturation under bright light.
The final aim of this research is to investigate the effects of zinc on the catalytic 
mechanism and structural stability of PDE6. Several different zinc-chelator systems were 
used to make solutions with defined concentrations of free zinc. We demonstrate that low 
concentrations of zinc are able to activate PDE6 catalytic activity, while high 
concentrations cause the loss of PDE6 activity.
CHAPTER 1
INTRODUCTION
1. Physiology of Rod and Cone Photoreceptor Cells
The vision of vertebrates is 
initiated in the highly differentiated 
photoreceptor cells in the retina.
Typically, there are two classes of 
photoreceptor cells in vertebrates, rods 
and cones, which exhibit different 
functional features of the light 
response and these functions are well 
suited to the ecological needs of 
vertebrates [Fig. 1-1. (Rodieck,
1998)].
1.1 Dark noise and single­
photon detection in rod photoreceptors
I ^  |
In darkness, rods are depolarized by the influx of Na and Ca through the 
cGMP-gated channels in the plasma membrane. Dark noise is the spontaneous
Fig. 1-1. Electron microscopic image 
of rods and Cones.
fluctuations in the electrical signal of the retina’s photoreceptors in the dark that is 
generated in the outer segment (Baylor et al., 1980), a specialized organelle dedicated to 
phototransduction. Noise in the dark circulating current consists o f three components: 
discrete photon-like events arising from thermal activation of the photopigment, 
continuous noise arising within the phototransduction enzymatic cascade, and 
fluctuations arising from gating and/or blocking transitions in the cGMP-activated 
channel. Of these, the first two components are considered the major sources of noise in 
the rod photoreceptor (Baylor et al., 1980;Rieke et al., 1996).
In rods, the amount of dark noise limits the behavioral sensitivity of rod vision 
(Baylor et al., 1984;Rieke et al., 1998): This is because large noise fluctuations may be 
mistaken for single photon responses and the noise may cause some single photon 
responses to be undetected. Rieke and Baylor (1996) showed that the smaller, continuous 
dark noise is generated by cGMP concentration fluctuations that result from spontaneous 
activation of the enzyme responsible for hydrolysis of cGMP, phosphodiesterase (PDE6). 
The spontaneous activation of PDE6 that results in this dark noise appears to be an 
intrinsic property of PDE6, and not due to activation by the phototransduction cascade 
(Rieke et al., 1996). Since the continuous component of dark noise is low in rods, a single 
photon photoresponse is large enough in amplitude to exceed the threshold for detection.
Cone photoreceptors have more dark noise than rods (Schneeweis et al., 1999) 
and the behavioral thresholds of cone vision are higher. Previous studies found that 
bleaching the photopigment reduced the dark noise in primate cones, suggesting that 
some noise originated from spontaneous pigment activation (Schnapf et al., 1990). In 
addition, the frequency composition of the dark noise was different from that of the dim
flash response (Schnapf et al., 1990;Schneeweis et al., 1999), suggesting an additional 
contribution to the noise downstream besides spontaneous photopigment activation. In 
salamander cones, the dominant noise in long wavelength-sensitive cones originated from 
the spontaneous activation of the photopigment, whereas the major noise of short 
wavelength-sensitive cones (in which the photopigment was relatively stable), arose in 
the transduction cascade (Rieke et al., 2000).
The difference in the level and the dominant sources of the dark noise in rod and 
cone photoreceptors suggests that different regulatory mechanisms must exist to regulate 
the absolute sensitivity in these two different classes of photoreceptor cells in the retina.
1.2 Light response in photoreceptor cells
Rod photoreceptors operate in dim illumination conditions by being able to 
reliably detect and absorb a single photon of light to generate an electrical response under 
fully dark-adapted conditions (Baylor et al., 1979). However, they undergo 
photoresponse saturation in moderately bright light conditions. Rods exhibit relatively 
slow photoresponses and their spatial distribution throughout the retina limits the acuity 
of vision. In contrast, cone photoreceptors are less sensitive to light than rods and operate 
under bright light conditions. A remarkable property of cones is that they can remain 
photosensitive without being saturated even under the condition of extremely bright light 
(Boynton et al., 1970). Cones are less responsive than rods to photons but their response 
is much faster. In addition, there are multiple classes of cone cells in the retina, each 
expressing a distinctive photopigment, which allows many animals to be able to 
discriminate colors.
1.3 Energy metabolism in rods and cones
As the most energetically demanding system in the brain, the retina uses ATP as 
energy to support multiple neuronal functions. In photoreceptor cells, the generation of 
energy relies more on oxidative than glycolytic metabolism and a greater consumption of 
energy is required in the dark than in the light (Ames, III et al., 1992).
In darkness, the ATP expenditure of a mouse rod is estimated to be about 9xl07 
ATP s"1 which is used primarily by the Na+/K+ATPase in the inner segment to pump out 
excess Na+ entering via the cGMP-gated channels in the outer segments. This ongoing 
entry of cations in the outer segment and their efflux out of the inner segment constitutes 
the circulating dark current (Baylor, 1996). Because mammalian rods and cones exhibit 
similar dark currents (Nikonov et al., 2006), the ATP expenditure of a cone in the dark is 
assumed to be similar to that of a rod. In bright light, the saturation of the light response 
in rods causes the cGMP channels to close and decreases the total energy consumption to 
2x 107 ATP s 1 (Okawa et al., 2008). In cones, the light response never allows the influx 
of Na+ through the cGMP-gated channels to fall further than about half that in the dark. 
As a result, the consumption of ATP of a cone in light is much greater than that in a rod. 
The 75% light-induced reduction in energy consumption in rods during photoresponse 
saturation provides an energy-efficient mechanism for high-sensitivity vision in dim light 
and reduced energy consumption in bright light.
The subcellular components in rods and cones also provide some evidence for 
their different energy consumptions. As an important enzyme for energy generation in 
mitochondria, the cytochrome c oxidase expression levels reflect the oxidative capacity 
of cells in order to match local energy demand (Wong-Riley, 2010). In the ellipsoid 
portions of photoreceptor inner segments, the mitochondria with highly active
cytochrome c oxidase are much larger and more abundant in cones than those in rods, 
resulting in a three-fold greater total surface area of inner mitochondrial membrane in 
cones than that in rods (Wong-Riley, 2010). This observation also indicates that cone 
photoreceptors utilize more electron transport chain enzymes to generate more ATP 
(Perkins et al., 2003;0kawa et al., 2008) to meet its higher level of energy metabolism. 
The efficient manner of energy consumption in rods may help us understand the 
evolutionary meaning of the duplex retina in vertebrates and also explain why there are 
relatively few cones in some diumal animals (Okawa et al., 2008).
2. Cellular Biology of Rod and Cone Photoreceptor Cells
2.1 Morphology of rods and 
cones (Fig. 1-2.)
The cellular structure of rods 
and cones is highly specialized for 
light capture and signal transmission 
(Rodieck, 1998). In structure, rods 
and cones are quite similar and both 
rods and cones consist of three major 
compartments: the outer segment, the 
inner segment and the synaptic 
terminal. The outer segment of 





















membranous disks which are developed from the highly expanded and convoluted 
plasma membrane. The visual pigments which absorb photons and trigger the visual 
signaling pathway, as well as some other signaling components needed to generate the 
electrical response, are embedded on the tightly stacked disks. Rods and cones display 
different structures in their outer segments. In rods, the outer segment is a stack of 
thousands of completely internalized, physically distinct disk membranes, whereas the 
outer segment in cones consists of continuous infoldings of the plasma membrane (Collin 
et al., 2004). The inner segments of both rods and cones are similar and they contain 
nuclei and other organelles required for normal cellular metabolism. In the visual 
signaling pathway, the electrical signal generated in the outer segment is transferred to 
the synaptic terminal and results in neurotransmitter release. The specialized structure of 
photoreceptor cells allows the transmission of light energy into a biochemical response 
and the subsequent of the electrical communication between photoreceptor cells and 
neighboring retinal neurons.
3. Visual Phototransduction Pathway in Photoreceptor Cells
The absorption of a photon by a visual pigment molecule (opsin) initializes visual 
transduction in photoreceptor cells. Visual transduction occurs in the outer segments of 
rods and cones and efficiently converts the light signal to an electric response, 
transferring it to other neurons. The phototransduction cascade consists of several 
proteins residing in the outer segment, including opsin, transducin, photoreceptor
6
phosphodiesterase (PDE6), regulator of G-protein signaling 9 (RGS9-1), type 5 G-protein 
|3-subunit (G(35-L), guanylate cyclase, opsin kinase and arrestin.
3.1 Visual excitation (Fig. 1-3.)
The excitation of visual transduction begins when a photon causes cis-trans- 
isomerization of the chromophore 11-c/s-retinal on rhodopsin (opsin in cones), which 
induces a conformational transition into the active state of rhodopsin, R*. The active R* 
is able to bind to and activate a photoreceptor-specific, heterotrimeric G protein,
transducin (Bums et al., 2001). The a subunit of transducin (Ta) binds guanine




Fig. 1-3. Visual excitation in photoreceptor cells.
The components of phototransduction cascade are localized on the disk 
membranes. Visual excitation is initiated with the absorption of photons by 
rhodopsin (R). The photoactivated rhodopsin (R*) binds to and activates transducin 
(TaPy) by exchanging GDP for GTP. The activated a-subunit of transducin (Ta*) 
dissociates from the P- and y-subunits and binds to the photoreceptor 
phosphodiesterase (PDE6). The inhibitory y-subunit of PDE6 is displaced by Ta*, 
and PDE6 is activated to hydrolyze cGMP. The drop of the cGMP level causes the 
closure of cGMP-gated ion channels and the hyperpolarization of the plasma 
membrane.
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nucleotides and attaches to the outer segment membrane by its acylated N-terminus; the 
isoprenyl moiety of the y-subunit of transducin anchors both y- and (3- subunits to the 
membranes. The binding of R* to transducin allows bound GDP to exchange for GTP. 
Upon the binding of GTP, Ta becomes activated (Ta*), and then dissociates from the T0y 
dimer (Arshavsky et al., 2002). Active Ta* is able to bind to its effector, photoreceptor 
phosphodiesterase (PDE6) which causes displacement of the inhibitory y-subunit of 
PDE6. The displacement of this inhibitory subunit (Py) from the catalytic dimer (Pa{3) 
allows the exposure of the catalytic pocket on PDE6 and triggers the rapid hydrolysis of 
cGMP. The rapid drop in cGMP concentration in the cytoplasm during light activation 
results in the dissociation of cGMP from the CNG ion channel in the plasma membrane, 
followed by closure of the channel. After the CNG ion channel closes, the inward cation 
current is eliminated; this results in the hyperpolarization of the membrane and generates 
a transient photoresponse. The photoresponse persists until the phototransduction proteins 
become deactivated.
3.2 Inactivation of visual excitation (Fig. 1.4)
The recovery to the dark-adapted state in photoreceptor cells following visual 
excitation is a precisely regulated procedure in which all the activated phototransduction 
proteins in the excitation pathway must be deactivated in order to restore the dark- 
adapted cGMP concentration and to reopen the CNG ion channels. The deactivation of 
each component in the excitation pathway in phototransduction is controlled by an 
individual mechanism.
Rhodopsin is deactivated through phosphorylation at several C-terminal sites by a 
specific G protein-coupled receptor kinase (Maeda et al., 2003). Following rhodopsin
phosphorylation, arrestin binds and deactivates rhodopsin (Fig. 1-4A). The high-affinity 
binding of arrestin to rhodopsin also blocks the interacting region between rhodopsin and 
transducin. The phosphorylation of rhodopsin is regulated by recoverin, a calcium- 
binding protein whose activity is also well controlled through the level of calcium in 
photoreceptor cells (Hurley, 1994).
The inactivation of Ta* requires hydrolysis of its bound GTP by accelerating its 
intrinsic GTPase activity and it is defined as the rate-limiting step in the recovery state of 
rod phototransduction. The GTPase rate of transducin is determined by a complex of 
proteins including Ta*-GTP, RGS9-1, G[35-L and the RGS9-1 anchor protein (R9AP) 
(Anderson et al., 2009). The inhibitory y-subunit of PDE6 is also found to play an
GTPase
Fig. 1-4. Inactivation of visual excitation.
A. Activated rhodopsin (R*) is phosphorylated at several C-terminal sites by 
rhodopsin kinase (RK) and the phosphorylation allows the binding of arrestin (Arr), 
which deactivates rhodopsin and blocks the interacting sites between rhodopsin and 
transducin. B. Activated transducin (Ta*) is deactivated by the hydrolysis of bound 
GTP through its intrinsic GTPase activity. The RGS9-1 complex (including RGS9- 
1, Gp5L, and R9AP) accelerates the GTPase rate of Ta*. Deactivated Ta 
dissociates from PDE6 and rebinds to T(3y.
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important role in this deactivation process by binding itself to RGS9-1 and enhancing the 
affinity of the RGS9-1 protein complex (Guo et al., 2011). After Ta hydrolyzes the bound 
GTP, it reforms the heterotrimer with Tpy and returns to its inactive state. The inhibitory 
y-subunit then binds back to the catalytic dimer of PDE6 and deactivates it.
As the central effector enzyme in phototransduction, PDE6 has to be precisely 
deactivated after light illumination to tightly control the excitation and recovery states in 
photoreceptors. The deactivation of PDE6 is processed through the releasing of the 
inhibitory y-subunit (Py) from the inactive a-subunit of transducin. Py rebinds to the 
catalytic dimer of PDE6 and re-inhibits the enzyme activity of PDE6. There exists a 
feedback regulation mechanism in which the strength of the interaction of Py for 
transducin versus the catalytic dimer of PDE6 is modulated by the binding state of cGMP 
to the non-catalytic binding sites on the PDE6 GAF domain (Norton et al., 2000).
Another deactivation mechanism is found in transgenic mice overexpressing Py, which 
suggests that free Py is able to bind and inhibit Ta* activated PDE6 (Tsang et al., 2006). 
Other regulatory mechanisms are required to completely explain the deactivation 
mechanism of PDE6 and studies on PDE6 binding partners may provide insight into the 
mechanism of PDE6 inactivation.
3.3 Light adaptation in photoreceptor cells
In addition to excitation and inactivation in phototransduction, photoreceptor cells
employ another process termed light adaptation to avoid photoresponse saturation under
bright light and to control the amplitude and kinetics of the photoresponse in presence of
constant illumination. In light adaptation, the reactions in excitation and inactivation are
desensitized so that the photoreceptor cells can detect and respond to the light intensity
10
over a wider range of illumination. Previous studies have found that several 
desensitization reactions are mediated by calcium in light adaptation. Guanylate cyclase 
(GC) can be regulated by calcium level through Ca2+ binding proteins, GC-activating 
proteins (GCAPs). When the intracellular Ca2+ level is reduced upon light activation, 
GCAPs stimulate GC to synthesize cGMP. This Ca2+/GCAP-dependent regulation of GC 
activity is a powerful feedback mechanism in which the rate of cGMP synthesis increases 
as Ca2+ levels fall during the response to light, helping to restore cGMP levels and 
allowing the cGMP channels to reopen (Stephen et al., 2008). The drop of Ca2+ 
concentration also affects the function of another Ca2+ binding protein, recoverin. The 
Ca2+ bound recoverin inhibits the phosphorylation of rhodopsin by GRK1 (Klenchin et al., 
1995). Interestingly, this inhibition by recoverin of rhodopsin phosphorylation requires 
greater and lengthier changes in intracellular Ca2+ concentration, which suggests that the 
regulation of calcium by recoverin only occurs in light adaptation but not in excitation of 
visual transduction. Another calcium-dependent mechanism in light adaptation involves 
calmodulin or calmodulin-like proteins to regulate the sensitivity of CNG channels. In the 
light, the fall of Ca2+ causes the dissociation of calmodulin from the channel and 
increases the sensitivity of the channel to cGMP, so the channel is able to operate at a 
lower cGMP level during light adaptation (Hsu et al., 1993).
However, a study on the current of light-adapted transgenic mouse rods in which
GCAPs have been ablated suggests that a novel Ca2+-dependent modulation of PDE6
may be occurring (Chen et al., 2010). Furthermore, the observation that acceleration of
the falling phase of the light response in Py-overexpressed transgentic rods indicates that
the decline of light-activated PDE6 activity is responsible for the decline of the light
11
response (Tsang et al., 2006). Both studies suggest that currently accepted Ca2+- 
dependent mechanisms for light adaptation cannot explain the physiological data and that 
and the modulation of PDE6 may also play a critical role in light adaptation. However, 
the mechanism of PDE6 regulation during light adaptation is unknown and further work
2  j 2 1
is needed to provide biochemical evidence for Ca -dependent or Ca -independent 
regulatory mechanism (Fain, 2011).
3.4 Dark-adaptation
Dark adaptation is defined as the slow recovery of visual sensitivity after 
exposure to a strong light. Although the detailed cellular and molecular mechanism of 
dark adaptation is unclear, some predictions based on physiological and biochemical 
experiments have been made to partially explain it. Lamb and Pugh reported that the dark 
recovery time in photoreceptors is dependent on the level of the bleaching of visual 
pigments (dependent on the light intensity and exposure time) and the rate of visual 
pigment regeneration (Lamb et al., 2004).
Rhodopsin is a member of the superfamily of seven-helix, G-protein-coupled 
receptor proteins (GPCRs) and in its inactive state, there is a light-absorbing 
chromophore (11 -cis retinal form) bound to it, while the absorption of a photon can 
isomerize the chromophore to the all-trans configuration and activates rhodopsin to 
interact with transducin, a G protein (Palczewski, 2012). After the photoresponse, the all- 
trans retinal dissociates from the opsin to regenerate rhodopsin. The regeneration of 
rhodopsin consists of the synthesis of 11-cz's retinoid in the retinal pigment epithelium, 
the delivery of it to the outer segment in photoreceptor cells and the removal and storage
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of all-trans retinal. It is believed that the regeneration of visual pigments is the rate- 
limiting steps in dark adaptation (Lamb et al., 2004).
In the dark-adapted state, the circulating “dark current” in photoreceptor cells is 
maintained by the influx of Na+ and Ca2+ through the partially opened CNG ion channels 
in the outer segment plasma membrane. The extrusion of Na+ is accomplished by a 
Na+/K+-ATPase on the inner segment membrane and the efflux of K+ by the K+ channels 
on the inner segment membrane. The Na+/Ca2+-K+ exchanger localized on the outer 
segment membrane and some other ion channels in the inner segment are also involved in 
regulating ion conduction and transport in photoreceptors (Cote, 2008;Matulef et al., 
2003;Molday et al., 2000).
In summary, the biochemical and physiological features in excitation, recovery 
and adaptation in phototransduction have been studied for decades, and multiple 
collaborative or independent regulatory mechanisms involved in this sophisticated 
signaling pathway have been discovered. However, we still lack sufficient knowledge to 
completely explain some physiological phenomena. How is PDE6 modulated during light 
adaptation? What regulatory mechanisms reduce energy consumption in rod 
photoreceptors exposed to bright light and how do cones differ from rods? How is the 
spontaneous activation of PDE6 in rods suppressed to reduce dark noise and enhance the 
sensitivity of rods to single photons? As the central effector of visual transduction, PDE6 
plays a critical role. The central hypothesis of this thesis is that novel PDE6 interacting 
proteins may contribute to regulation of the enzymatic activity of the rod enzyme in its 
dark-adapted and light-activated states.
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4. Structure and Functions of PDE6
4.1 The PDE superfamily
In mammals, the cyclic nucleotide phosphodiesterase (PDE) superfamily consists 
of 11 family members derived from more than 20 genes, which are distributed in various 
types of tissues. Functionally, PDEs catalyze the hydrolysis of cAMP and cGMP to 
produce 5’-AMP and 5’-GMP. In coordination with adenylate cyclase (AC) and 
guanylate cyclase (GC), PDEs regulate the cellular levels of these second messengers in 
multiple signaling pathways. In the PDE superfamily, some members are highly specific 
for hydrolysis of cAMP (PDE4, 7 and 8) or cGMP (PDE5, 6 and 9), while the others 
hydrolyze both cAMP and cGMP (PDE1, 2, 3, 10 and 11) with certain preferences 
(Bender et al., 2006). The activity of PDEs is precisely modulated in cells to be 
responsible for various stimulations such as cytokines, oxidative influences, and light. 
Dysfunctions of PDEs have been reported to be closely related with a large number of 
diseases such as erectile dysfunction (ED; PDE5) and retinitis pigmentosa (RP) (PDE6). 
Several PDE inhibitors have been used clinically, for example, the inhibitors of PDE5 are 
used to for the treatment of ED (Barnett et al., 2006) and more PDE inhibitors are under 
development to provide treatments for many diseases.
Among the PDE superfamily members, PDE6 and PDE5 are most closely related.
PDE5 is abundant in vascular and airway smooth muscle, platelets, cerebellar Purkinje
cells, gastrointestinal epithelial cells and endothelial cells (Francis et al., 2006;Francis et
al., 2011). PDE6 is expressed primarily in retinal photoreceptors in great abundance and
is also found in the pineal gland and certain melanoma cells (Cote, 2006). Both PDE5
and PDE6 contain GAF domains (named for their occurrence in cGMP binding PDEs,
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certain adenylate cyclases and the Escherichia coli FhlA protein) in their regulatory 
regions, share similar amino acid sequence, strongly prefer cGMP over cAMP as a 
substrate and present overlapping pharmacological profiles for inhibitors (Zhang et al., 
2005b). However, PDE6 is unique in its inhibitory subunit, catalytic efficiency and 
regulatory mechanisms as presented below.
4.2 The structure and function of PDE6
Physiologically, the PDE6 family is important for visual transduction in the retina. 
Mutations in each of the genes for the catalytic subunits (PDE6A, PDE6B and PDE6C) 
or the inhibitory y subunits (PDE6G and PDE6H) have all been found to associate with 
retinal degenerative diseases (Ferrari et al., 2011). For example, 10% of retinitis 
pigmentosa (RP) cases involve defects of cyclic nucleotide metabolism due to a gene 
defect in PDE6. In order to provide a fundamental study for treatment of retinal diseases, 
the structure, function and regulatory mechanisms of PDE6 have to be better understood.
The primary sequences of PDE6 expressed in rods and cones are highly conserved 
while they present distinct structural features. Rod PDE6 is a heterotetramer composed of 
two catalytic subunits, a (gene name, PDE6A) and P (PDE6B), forming a catalytic dimer, 
as well as two high-affinity associated inhibitory y-subunits (PDE6G). Cone PDE6 is also 
a heterotetramer but it has two identical catalytic a ’ subunits (gene name, PDE6C) and 
two inhibitory y’-subunits (PDE6H). The different structures of PDE6 in rods and cones 
may reflect their distinct cellular functions in visual transduction.
4.2.1 The catalytic subunits of rod PDE6
The atomic-level structure of rod PDE6 is not resolved since its catalytic subunits
cannot be heterologously expressed in a soluble and active state in biochemical quantities
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and it is difficult to purify large quantities of native PDE6 from photoreceptor cells 
(Zhang et al., 2004b;Muradov et al., 2006). So far, two 
microscopy (EM) density maps of PDE6 at low 
resolution (18A and 28A) have been reported (Goc 
et al., 2010;Kameni Tcheudji et al., 2001). The 
crystal structures of a nearly full-length PDE2 
(another GAF domain containing PDE), a chimeric 
PDE5/PDE6 catalytic domain and a cone PDE6 
GAFa domain have been resolved (Pandit et al.,
2009;Barren et al., 2009;Martinez et al., 2008). Each 
PDE6 catalytic subunit consists of N-terminal 
tandem GAF domains (GAFa and GAFb), a catalytic domain and a C-terminal motif that 
is post-translationally modified by isoprenylation.
The GAF domains (GAFa and GAFb) on the N-terminus of PDE6 are capable of
inducing allosteric changes that can regulate enzymatic activity (Cote et al., 2010). This
allosteric change is found to be an indirect regulation (Arshavsky et al., 1992b;Mou et al.,
2001)in which the inhibitory y subunit mediates the feedback and cross talk between the
GAF domain and catalytic domain. Direct interactions of the N-terminal half of the y-
subunit with GAFa and GAFb have been identified by crosslinking experiments
(Muradov et al., 2002;Guo et al., 2008). In addition, the GAFa domain contains a high-
affinity cGMP binding site(Yamazaki et al., 1980;Gillespie et al., 1988;Gillespie et al.,
1989a;Cote et al., 1993) and the high-affinity binding of cGMP to the GAFa nucleotide
binding pocket is stabilized by the central, polycationic region of the y subunit (Mou et
16
negative-staining electron
Kameni et al., 2001
Fig. 1-5. Electron 
microscopic image of PDE6.
al., 2001). The function of GAFb is unclear while some observations suggest an 
important role for GAFb in linking allosteric changes in GAFa to the regulation of the 
catalytic domain. In addition to allosteric regulation and ligand binding, the GAF 
domains are also involved in the dimerization of the catalytic dimer (Muradov et al., 
2003).
The structure of the catalytic domain of PDE6 has been analyzed based on the
PDE5 catalytic domain as a structurally homologous modeling template. It is likely to
consist of 16 a-helices (Conti, 2004) and two metal ions (zinc and magnesium) (He et al.,
2000a) that are coordinated by a group of six invariant residues present in all 11 PDE
families to form an integral part of the active site of PDE6. PDE6 presents a 500-fold
greater catalytic efficiency for cGMP as compared to PDE5. The light-activated PDE6
hydrolyzes cGMP with a catalytic constant ( £ Ca t)  of 5500 s'1 in bovine rod photoreceptors.
The catalytic efficiency (^cat/^m ^xlO ^'V 1) for cGMP approaches the diffusion-
controlled limit (Cote, 2006), which is essential for light-induced changes in cGMP levels
to occur on the millisecond timescale needed for the physiological response of rods and
*
cones to illumination(D'Amours et al., 1999;Arshavsky et al., 2002). The regulation of 
the catalytic activity by the inhibitory y-subunit is a unique feature of the PDE6 catalytic 
domain as compared with PDE5. The removal of both y subunits in PDE6 activates the 
enzyme 300-fold (Mou et al., 1999).
17
Fig. 1-6. The structure of rod PDE6 holoenzyme.
Rod PDE6 is a heterotetramer composed of two catalytic 
subunits (a and (5) forming a catalytic dimer, and two 
inhibitory y-subunits. Each of the catalytic subunits 
contains a catalytic domain and a noncatalytic cGMP- 
binding site (occupied by circles) in the regulatory GAF 
domain. The inhibitory y-subunit binds to PDE6 with high 
affinity and blocks the active site to prevent cGMP 
hydrolysis in its nonactivated state.
Divalent cations such as Mg2+ and Zn2+ are important for the catalytic activity of 
PDE6. Previous studies found that the concentration of Mg2+ changes the apparent Km of 
PDE6 for cGMP (Srivastava et al., 1995) and rod PDE6 requires tightly-bound zinc for 
its catalytic activity (He et al., 2000a). The stoichiometry between PDE6 and endogenous 
zinc has been determined to be 3-4 g atoms of zinc per mole PDE6, which suggests that 
there are two tightly bound zincs per catalytic subunit (He et al., 2000a). The loss of 
PDE6 activity caused by the removal of the high-affinity bound zinc was able to be fully 
recovered by magnesium, manganese or cobalt. Dipicolinic acid (DPA) and EDTA can 
remove the majority of the tightly-bound zinc, which causes the complete loss of activity 
of PDE6 even in the presence of magnesium, but the lost activity could be restored by the 
addition of zinc (He et al., 2000a).
The C-terminus of PDE6 catalytic subunits presents one CAAX motif (A, 
aliphatic; X, any amino acid) which is subjected to post-translational modification. The 
a-subunit of rod PDE6 is famesylated at the first cysteine residue of the terminal 
sequence CC(I/V)Q, whereas the p-subunit has a geranylgeranyl group bound to the 
cysteine of the terminal sequence C(C/R)IL (Qin et al., 1992;Anant et al., 1992). The
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prenylated, carboxymethylated C-termini are hydrophobic and are responsible for 
anchoring PDE6 to the outer segment disk membrane (Catty et al., 1991).
4.2.2 The inhibitory y subunit of PDE6
The PDE6 family is unique in having a high-affinity inhibitory y subunit (Py) 
associated to the catalytic dimer. The 87-amino acid rod inhibitory subunit is a natively 
unfolded protein with little secondary structure(Berger et al., 1997;Uversky et al., 2002), 
while it is remarkable for the variety of regulatory functions it performs as well as the 
multitude of proteins with which it interacts in addition to the catalytic subunits of PDE6 
(Guo et al., 2008). Primarily, Py regulates cGMP hydrolytic rates by controlling access of 
cGMP to the catalytic pocket of PDE6 through the interaction between the last few C- 
terminal residues of Py and the catalytic domain (Granovsky et al., 1997;Zhang et al.,
2010b).There is also an allosterically mediated inhibition of catalysis that occurs in the 
absence of the C-terminal residues of Py (Zhang et al., 2010a). The central region of Py, 
with high affinity for the catalytic dimer (Mou et al., 2001), is found to enhance the 
binding affinity of cGMP to the noncatalytic binding sites within the regulatory domain 
of PDE6 (Cote et al., 1994).
In addition to the PDE6 catalytic dimer, Py also interacts with other
phototransduction proteins and mediates important regulatory mechanisms of PDE6. The
N-terminal region of Py (a.a. 24-45) has been reported to interact with transducin a-
subunit. This interaction increases cGMP dissociation from noncatalytic cGMP binding
sites on PDE6 (Morrison et al., 1989;Muradov et al., 2010;Zhang et al., 2012). During the
activation of PDE6 by transducin, the glycine-rich region of Py (a.a. 45-62) is required as
a “docking site” to stabilize the binding of Ta* and thereby develop additional
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interactions with the C-terminal Py (a.a. 71-86) that lead to de-inhibition of PDE6 
catalysis(Zhang et al., 2012;Artemyev et al., 1992). In the recovery state of 
phototransduction, Py serves to facilitate the formation of a tighter RGS9-1 complex to 
potentiate the GTPase accelerating function of RGS9-1 (He et al., 1998;Hu et al., 2002). 
Previous work suggests that C-terminal region of Py can bind to RGS9-1 (Slep et al.,
2001) and recent work in our lab reveals that the region of a.a. 55-62 is also important for 
GTPase acceleration of the Ta*/RGS9-1 complex (Zhang et al., 2012).
5. PDE6 Interacting Proteins
■»
As referred to in previous sections, transducin is a PDE6 interacting protein in 
photoreceptor cells. In visual excitation, the rhodopsin-activated transducin (Ta*-GTP) 
binds to PDE6 holoen2yme and displaces the inhibitory y-subunit from the catalytic 
pocket, which leads to the activation of PDE6. Multiple interacting sites have been 
identified between transducin and Py (Granovsky et al., 2001;Slep et al., 2001;Zhang et 
al., 2012). It has been assumed that transducin can activate PDE6 in a 1:1 molar ratio 
(Wensel et al., 1990;Leskov et al., 2000), but the model of transducin activation of PDE6 
in which transducin is hypothesized to relieve y-subunit inhibition at either one or both 
catalytic sites of PDE6 is unclear.
In addition to transducin, the prenyl binding protein (PrBP/8) is considered a
PDE6 interacting protein. PrBP/8 was originally found to be co-purified with soluble
bovine rod and cone PDE6 and referred to as the 8-subunit of PDE6 (Gillespie et al.,
1989b). This 17-kDa protein is ubiquitously expressed and interacts with numerous
proteins, most of which are post-translationally modified with famesyl or geranylgeranyl
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groups (Zhang et al., 2004a). In photoreceptor cells, PrBP/8 transports prenylated 
proteins including PDE6, opsin and the retinitis pigmentosa G protein regulator (Florio et 
al., 1996;Gillespie et al., 1989b;Zhang et al., 2005a) from the inner segment to the outer 
segment where phototransduction occurs (Karan et al., 2008). In vitro, it has been shown 
that PrBP/5 binds PDE6 with high affinity through the specific interaction with the 
famesylated and geranylgeranylated C-termini of rod PDE6 catalytic submits resulting in 
the release of PDE6 from its disk membrane attachment site (Goc et al., 2010;Norton et 
al., 2005). Although the binding of PrBP/5 to PDE6 has no effect on the catalytic activity 
of PDE6, it has been found to reduce the ability of activated transducin to activate PDE6 
(Norton et al., 2005) and enhances the nucleotide exchange at the non-catalytic cGMP 
binding sites of PDE6 (Mou et al., 1999;Gillespie et al., 1989b). PrBP/8 may play a role 
in negative feedback regulation of PDE6 activation, perhaps during prolonged light 
adaptation (Cote, 2008).
Another PDE6 interacting protein is aryl hydrocarbon receptor-interacting
protein-like 1 (AIPL1), a photoreceptor-specific chaperone of PDE6. AIPL1 is expressed
in the retina and the pineal gland (Van der Spuy et al., 2002) and mutations on the Aipll
gene result in one of the most clinically severe forms of Leber congenital amaurosis
[LCA type 4; (den Hollander et al., 2008)]. In structure, AIPL1 shares similar sequence
information and domain organization with the ubiquitously expressed aryl hydrocarbon
receptor-interacting protein (AIP) (Sohocki et al., 2000). AIPL1 consists of an N-terminal
FK506-binding protein (FKBP)-like domain and a C-terminal tetratricopeptide repeat
(TPR)-domain (Sohocki et al., 2000;Das et al., 1998) and these domains are believed to
be related with its chaperone activity (Van der Spuy, 2006). AIPL1 is considered as an
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essential component of a retina-specific chaperone complex for the reason that it was 
found to interact with Hsp90 and Hsp70 (Hidalgo-de-Quintana et al., 2008;Schwartz et 
al., 2006;Kosmaoglou et al., 2008). Transgenic research found that the expression level 
and activity of PDE6 were largely reduced in the AIPL1 knockout mice, which suggests 
that AIPL1 is critical for the expression and function of PDE6 (Ramamurthy et al., 2004). 
Previous studies suggest that AIPL1 functions on the famesylated modification of the rod 
PDE6 a subunit and stabilizes the PDE6 holoenzyme structure by properly assembling it 
to avoid rapid protein degradation (Kolandaivelu et al., 2009). Recently, it has been 
reported that AIPL1 is able to directly bind the famesyl lipid moiety and the potential 
famesy 1-binding sites have been identified on AIPL1, which suggests that the function of 
AIPL1 on PDE6 may require the binding of AIPL1 to the famesylated PDE6 a subunit 
(Majumder et al., 2013). However, further research is needed to fully understand the 
mechanism of AIPL1 action on PDE6 in photoreceptor cells.
In addition, the Regulator of G-protein Signaling 9-1 (RGS9-1) is considered as a
PDE6 interacting protein. The molecular organization of RGS9-1 consists of a catalytic
RGS domain that functions to stimulate GTP hydrolysis on the G-protein a-subunit (He
et al., 2000b;Skiba et al., 2001), a G protein gamma-like (GGL) domain which
specifically interacts with GPsL, and a DEP (Disheveled, Egl-10, Pleckstrin)/DHEX
(DEP helical extension) domain that mediates its interactions with RGS9 anchor protein
(R9AP) on the membrane (Anderson et al., 2009). In photoreceptor cells, the RGS9-1
complex, including RGS9-1, Ta*-GTP, G|35L and R9AP (Anderson et al., 2009), plays
an important role in recovery after light activation ceases. The process requires the
inactivation of Ta*-GTP through the intrinsic GTPase activity of Ta; the GTPase rate is
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considered the rate-limiting step in the recovery state of photoresponse (Krispel et al., 
2006). It is believed that RGS9-1 modulates the rapid deactivation process of Ta*-GTP 
by accelerating its GTPase rate, in which the association of RGS9-1 with G05L and 
R9AP is required (Keresztes et al., 2004;Krispel et al., 2003). Previous studies have 
reported that the C-terminal region of Py can bind to RGS9-1 (Slepak et al., 1995;Slep et 
al., 2001; Arshavsky et al., 1994) and the N-terminal half of Py can associate with the 
transducin/RGS9-l complex (Guo et al., 2011). Recent work in our lab confirmed that the 
maximal acceleration of the GTPase rate of the Ta*/RGS9-1 complex requires the C- 
terminal region (Ile-86, Thr-65 and Val-66) of Py and the amino acids 55-62 of Py 
facilitate the anchoring of Py to the Ta*/RGS9-1 complex and stabilize the interaction 
(Zhang et al., 2012). All these observations suggest that the interaction between Py and 
RGS9 serves to form a tighter RGS9-1 complex to potentiate the GTPase accelerating 
function of RGS9-1 (Hu et al., 2002).
6. Characteristics of the Glutamic Acid-Rich Protein2 (GARP2)
6.1 The cGMP-gated cation (CNG) channel in rod photoreceptor cells
As an essential component of the visual signaling pathway, the photoreceptor
cGMP-gated cation (CNG) channel plays a major role in light-dependent regulation of
the ion flow into rod or cone outer segments (Sarfare et al., 2007;Kaupp et al.,
2002;Matulef et al., 2003), as well as in maintenance of the structural integrity of rod
outer segments. Photoreceptor CNG channels come from the superfamily of voltage-
gated channels and are non-selective cation channels (Kaupp et al., 2002); in rods, 90%
of the current is carried by Na+ and 10% by Ca2+. The rod CNG channel is a
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heterotetramer composed of three a-subunits (gene name, CNGA1) and one (3-subunit 
(gene name, CNGB1), while the cone CNG channel consists of two cone a-subunits 
(CNGA3) and two cone P-subunits (CNGB3) subunits (Weitz et al., 2002;Zhong et al., 
2002;Shuart et al., 201 l;Weitz et al., 2002). The structure of CNGA1 and CNGB1 is 
composed of six transmembrane domains, a pore loop region, a cGMP binding domain 
and a C-terminal region (Shuart et al., 2011). CNGB1 has a unique glutamic acid and 
proline-rich region at the N-terminus (GARP region), and as well as two Ca2+/CaM 
(calmodulin) binding domains (CaM-1 and CaM-2)(Sarfare et al., 2007). In addition to 
the GARP region on CNGB1, there are two other forms of GARP—GARP1 and 
GARP2—in rod photoreceptors that represent alternative splicing products of the 
CNGB1 gene. In structure, CNGB1, GARP1 and GARP2 share the conserved N-terminus
GARP’ Glu-rich CaM P’domain cGMP
1394 a.a.
Cyclic nucleotide-gated channel p subunit (CNGB1)







Fig. 1-7. The GARP (glutamic acid-rich protein) family.
The p-subunit of cyclic nucleotide-gated channel (CNGB1), GARP1 and GARP2 
have the same N-terminal GARP’ region (GARP’). Both CNGB1 and GARP1 have 
the glutamate-rich domain (Glu-rich). CNGB1 also has a channel region including 
a calmodulin binding domain (CaM), transmembrane domain (p’ domain) and a 
cGMP binding domain (cGMP). GARP1 and GARP2 express different C-terminal 
ends, which are distinct from the sequence of CNGB1.
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while the translation of the CNGB1 gene was terminated at different exons—human 
CNGB1: exonl-33; human GARP2: exonl-12 with exon 12a; human GARP1: exon 1-16 
and exon (34b (Ardell et al., 2000).
In rods, the CNG channel is activated and opened by binding of cGMP to the 
cyclic nucleotide binding domain. During light activation, the drop in cGMP levels 
caused by hydrolysis of PDE6 allows the release of cGMP from the channel and results 
in the closure of the channel, which leads to hyperpolarization of the membrane potential 
of the rod photoreceptor. In addition to cGMP, the rod CNG channel is modulated by 
Ca2+ concentration through Ca2+/calmodulin binding to CNGB1. Under dark conditions, 
the intracellular Ca2+ and cGMP concentrations are high and Ca2+/calmodulin binds to the 
channel and the open channel presents a low affinity for cGMP binding. When light 
activation causes the closure of the channel and the drop of intracellular Ca2+ 
concentration, Ca2+ dissociates from the CaM and the affinity of cGMP to the channel . 
increases. The Ca2+/calmodulin modulation plays important role in the regulation of 
cGMP affinity which may be a feedback mechanism in light adaptation (Kaupp et al., 
2002).
5.2 The biochemical properties and functions of GARPs
CNGB1, GARP1 and GARP2 are only found in the outer segments of rod 
photoreceptor cells but not in cones. GARP2 is more abundant than CNGB1 in rods, 
whereas GARP1 is present in low abundance based on immunoblots. In structure,
GARP1 is 65 kDa and its amino acid sequence is almost identical to the GARP region of 
rod CNGB1; GARP2 is 32 kDa and its amino acid sequence corresponds to the first 291
amino acids of GARP1 but it presents a unique C-terminus of eight amino acids.
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Although GARP2 lacks the so-called GARP region (a.a. 355-465 on CNGB1), it still 
exhibits an abnormally high content of glutamate residues (Batra-Safferling et al., 2006). 
The large percentage of negatively charged residues on GARPs causes the higher 
apparent molecular weight on SDS-PAGE. Both GARP1 and GARP2 are considered as 
“natively unfolded” proteins with less secondary and tertiary structure as detected by 
biochemical and biophysical analysis (Batra-Safferling et al., 2006). In rods, biochemical 
assays suggest that CNGB1 and GARP2 interact with peripherin-2 in the rim region of 
the outer segment disk membrane (Poetsch et al., 2001). There also exists an interaction 
between GARPs and guanylate cyclase (GC), as well as the retina-specific ATP-binding 
cassette transporter (ABCR) (Korschen et al., 1999).
Several transgenic studies have demonstrated the critical roles for GARPs in 
maintenance of ROS structural integrity as well as normal retinal function. In CNGB1- 
deleted transgenic mice (in which the exon 26 of CNGBla gene was deleted to disrupt 
CNGB1 expression but normal GARP1 and GARP2 were expressed), the CNGA1 
subunit was rapidly degraded, the visual responses of rod photoreceptors were completely 
abolished, the length of the rod outer segment was shorter (ROS), the number of ROS 
was less, and the degeneration of the retina was faster (Huttl et al., 2005). In another 
transgenic mouse system in which all GARPs (CNGB1, GARP1 and GARP2) were 
ablated, the expression of CNGA1 subunit, GC1 and ABCA4 were greatly reduced, ROS 
was shorter and misaligned with abnormal elongated disks, and the sensitivity of rod 
photoreceptor cells to light was reduced (Zhang et al., 2009). Both of these transgenic 
studies suggested that the interaction between GARP2 and peripherin-2 is critical for
normal disk morphogenesis and integrity of the rod outer segment structure.
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The roles of GARP2 and peripherin-2 in the structure of ROS have been further 
evaluated through in situ bimolecular fluorescence complementation (BiFC) in transgenic 
Xenopus laevis rods. In this study, the interaction between CNGB1 and peripherin-2 was 
observed in rod inner segments initially before trafficking to outer segments, while 
GARP2-peripherin-2 interaction was only observed at sites of disk morphogenesis. This 
suggests that GARP2-peripherin-2 interaction directly participates in structuring disks 
and that the CNGB1-peripherin-2 complex functions to localize plasma membrane ion 
channels (Ritter et al., 2011).
As a rod-specific protein, GARP2 has been identified as a high-affinity PDE6 
binding protein that inhibits the basal activity of the PDE6 holoenzyme by up to 80 
percent (Korschen et al., 1999;Pentia et al., 2006). However, the precise regulatory 
mechanisms of GARP2 on the activity and life time of PDE6 in phototransduction are 
unclear. Recently, transgenic mice with overexpressed GARP2 were found to exhibit 
increased phototransduction gain, which suggests a potential role of GARP2 for 
modulating transducin activation (McKeon et al., 2012). The overall goal of this thesis is 
to evaluate the function of GARP2 in rod photoreceptors. To achieve this, I have 




CHARACTERIZATION OF THE BIOCHEMICAL AND 
BIOPHYSICAL PROPERTIES OF GARP2
Abstract
Glutamic Acid-Rich Protein-2 (GARP2) is a rod photoreceptor-specific protein of
299 amino acids with an unusually high content of glutamate residues. GARP2 has been
reported to interact with several membrane-associated phototransduction proteins
including phosphodiesterase (PDE6) in rod photoreceptors. As a high-affinity PDE6
binding partner, GARP2 has been demonstrated to suppress the basal activity of
nonactivated PDE6 but has no effect on activated PDE6. Considering the functional
differences between rod and cone photoreceptors, GARP2 may play an important role in
rod phototransduction, such as detecting single photons in the dark-adapted state and/or
regulating visual signaling pathways during rod photoresponse saturation. The goal of
this research is to characterize the properties of GARP2 and discover the functional
relevance of GARP2 for regulating PDE6 during visual transduction. Here we show that
an improved immunological method can be utilized to detect GARP2. We developed
methods in which native GARP2 can be selectively separated from PDE6 on rod outer
segment (ROS) membranes. Finally, we prepared purified, recombinant GARP2 and
show that it has similar biophysical properties as native GARP2. We propose that these
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biochemical and biophysical characteristics of GARP2 may be responsible for the 
regulation of PDE6 in rod photoreceptors.
Introduction
PDE6 is the central effector enzyme of visual transduction, and cGMP hydrolysis
by PDE6 must be precisely regulated to control the sensitivity, amplitude, and kinetics of
the photoresponse during excitation, termination and adaptation to light stimulation of
photoreceptor cells. Rod PDE6 is a heterotetramer composed of two catalytic subunits (a
and P) as well as two high-affinity associated inhibitory y subunits. Cone PDE6 is also a
heterotetramer but it has two identical catalytic a ’ subunits with two inhibitory y’
subunits. The different structures of PDE6 in rods and cones may reflect their distinctive
cellular functions in visual transduction. Each PDE6 catalytic submit consists of N-
terminal tandem GAF domains (GAFa and GAFb), a catalytic domain and a C-terminal
membrane-associated motif. The GAF domains (GAFa and GAFb) of the catalytic dimer
containing two non-catalytic cGMP binding sites (Yamazaki et al., 1980;Gillespie et al.,
1988;Gillespie et al., 1989a;Cote et al., 1993) are able to induce allosteric changes upon
ligand binding to regulate the catalytic activity of the catalytic domain (Arshavsky et al.,
1992b;Mou et al., 2001). The regulation of the catalytic activity by the inhibitory y
subunit, Py, is a unique feature of PDE6, in which both y subunits can be displaced by
transducin to activate PDE6 upon light stimulation. The inhibitory y subunit is a natively
unfolded protein with 87 amino acids (Berger et al., 1997;Uversky et al., 2002), and it is
remarkable for its variety of regulatory functions (Guo et al., 2008). First, Py regulates
cGMP hydrolytic rates by controlling access of cGMP to the catalytic pocket of PDE6
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(Granovsky et al., 1997;Zhang et al., 2010b). Second, Py enhances the binding affinity of 
cGMP to the noncatalytic binding sites within the regulatory domain of PDE6 (Cote et al., 
1994). Third, Py also interacts with other phototransduction proteins including transducin 
and RGS9-1 to mediate important regulatory mechanisms of PDE6 during excitation and 
recovery of the photoresponse (Zhang et al., 2012;He et al., 1998;Slep et al., 2001).
The activation mechanism of PDE6 by transducin is well studied. Following 
photoactivation of rhodopsin, activated transducin (Ta*-GTP) binds to the PDE6 
holoenzyme and displaces Py from the catalytic pocket, which leads to the activation of 
PDE6. Multiple interacting sites have been identified between transducin and Py 
(Granovsky et al., 2001;Slep et al., 2001;Zhang et al., 2012). In contrast, much less is 
known about other mechanisms that are thought to regulate PDE6 during recovery from 
light stimulation and during prolonged light adaptation.
Glutamic Acid-Rich Protein-2 (GARP2) is considered to be a potential regulatory
protein of PDE6. GARP2 is a splice variant of the rod cGMP-gated channel P-subunit
[CNGB1; (Sugimoto et al., 1991)], which is found to be restricted to the outer segment of
rod photoreceptors, but not in cones. GARP2 is a 299-amino acid protein, of which the
first 291 amino acids correspond to those of CNGB1, along with a unique eight-amino
acid C-terminus. Although GARP2 lacks the “GARP region” (a.a. 355-465 of CNGB1),
it still exhibits abnormally high content of glutamate residues (Batra-Safferling et al.,
2006). As a result of the high number of negatively charged residues, a greater apparent
molecular weight (~60 kDa) on SDS-PAGE is observed than the calculated molecular
weight of GARP2 (32 kDa). The high content of proline and glutamate residue also
contributes to the low hydrophobicity of GARP2 as an acidic protein (Batra-Safferling et
30
al., 2006). GARP2 is considered to be a “natively unfolded” protein with low amount of 
secondary and tertiary structure. Some biochemical assays suggest that GARP2 interacts 
with peripherin-2 in the rim region of the outer segment disk membrane in the rods 
(Poetsch et al., 2001). GARP2 also interacts with other phototransduction proteins 
including PDE6, guanylate cyclase (GC), and retina-specific ATP-binding cassette 
transporter (ABCR) (Korschen et al., 1999).
Although GARP2 is abundant in the outer segments of rods, its functions in rod
photoreceptor cells are not clear. Using transgenic mice, several studies have
demonstrated that GARPs are critical for maintaining the structural integrity of ROS and
the normal physiological functions of the retina. In CNGB1 -deleted transgenic mice, in
which CNGB1 expression was disrupted but normal GARP1 and GARP2 were expressed,
it was observed that the CNGA1 subunit was rapidly degraded, the retina degenerated
faster, and the visual response of rod photoreceptor cells was completely abolished. In
addition, the length of ROS was shorter and the number of ROS was less, while the
morphological organization of discs and the rim regions of ROS were found to be normal
(Huttl et al., 2005). With another transgenic mouse system in which the expression of all
GARPs (CNGB1, GARP1 and GARP2) was abolished, the sensitivity of rod
photoreceptor cells to light was greatly reduced, the expression of CNGA1 subunit, GC1
and ABCA4 were greatly reduced, and ROS were shorter and misaligned, with abnormal
elongated disks (Zhang et al., 2009). Recently, transgenic mice with overexpressed
GARP2 were found to exhibit an increased phototransduction gain, which suggests a
potential role of GARP2 in transducin activation (McKeon et al., 2012). In situ
bimolecular fluorescence complementation (BiFC) in transgenic Xenopus laevis rods
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suggested that GARP2-peripherin-2 interactions may directly participate in structuring 
disks of the rod outer segment, and that the CNGB1-peripherin-2 complex may function 
to localize plasma membrane ion channels (Ritter et al., 2011).
As a rod-specific protein, GARP2 has been identified as a high-affinity PDE6 
binding protein that inhibits the basal activity of PDE6 holoenzyme by up to 80 percent 
(Pentia et al., 2006). However, the precise regulatory mechanisms of GARP2 on the 
activity and lifetime of PDE6 in phototransduction are still unclear. We propose that 
GARP2 is involved in the unique phototransduction function of rods, in which GARP2 
may regulate PDE6 to reduce its “dark noise”, enhance its sensitivity and reduce cGMP 
metabolic flux to conserve metabolic energy during rod photoresponse saturation. The 
overall goal of this chapter is to better understand the biochemical and biophysical 
characteristics of GARP2 in order to discover the functional relevance of GARP2 for 
regulating PDE6 during visual transduction.
Materials and Methods
Materials—Bovine retinas were purchased from W.L. Lawson, Inc. The Superdex
200 and Mono-Q columns and the Butyl-Sepharose chromatography media were from
GE Healthcare. The Ni-nitriloacetic acid (NTA) His-Bind resin was obtained from
Novagen and glutathione-agarose was from Thermo-Fisher/Pierce. Filtration and
ultrafiltration products were from Millipore. Mouse monoclonal anti-GARP2 antibody
(8G8) to the first 15 amino acid of GARP2 was a generous gift from Dr. Robert Molday
(University of British Columbia). Rabbit polyclonal anti-GARP antibody to bovine
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sequences common to GARP1, GARP2 and the rod (3-subunit CNGB1 (FPc) was a kind 
gift of Dr. Benjamin Kaupp (Institut fur Biologische Informations verarbeitung, Jiilich, 
Germany). Chicken anti-GARP2 antibody (SP) to the first 15 amino acid of GARP2 was 
a generous gift from Dr. Steven Pittler (University of Alabama at Birmingham). Rabbit 
anti-GARP2 antibody against the last 8 amino acid of GARP2 (ABR) is purchased from 
Pierce. Affinity-purified anti-peptide rabbit polyclonal antibodies directed to the PDE6 
GAFb domain (NC397-64), the C-terminus of the Py-subunit of PDE6 (CT-9710) and to 
full-length bovine PrBP/8 (FL-R98) were prepared in our laboratory. Monoclonal mouse 
ROS antibody against PDE6 holoenzyme was affinity purified in our lab. Full-length 
recombinant bovine PrBP/5 was kindly provided by Dr. Karyn Cahill and Hannah 
Gitschier. Mouse Anti-His tag antibody was obtained from Cell Signaling. All other 
chemicals were obtained from Sigma Chemical Co. or from Thermo-Fisher.
Rod Outer Segment (ROS) Membrane Isolation and Purification—ROS 
membranes from bovine retina were prepared as described previously (Pentia et al., 2005). 
Briefly, ROS was isolated from frozen bovine retinas on a discontinuous sucrose gradient 
under dark conditions and stored at -80 °C. ROS membranes were homogenized in an 
isotonic buffer (10 mM Tris, pH 7.5, 60 mM KC1, 40 mM NaCl, 2 mM MgCk, 1 mM 
dithiothreitol, 0.3 mM phenylmethylsulfonyl fluoride) using a glass, handheld 
homogenizer. The soluble proteins and ROS membrane were separated by centrifugation.
Purification o f PDE6 Holoenzyme (Pafiyy) and PDE6 Catalytic dimer (Paf)—
Rod PDE6 holoenzyme was extracted with a hypotonic buffer (5 mM Tris, pH 7.5,1 mM
EDTA-2Na, 1 mM dithiothreitol, 0.3 mM phenylmethylsulfonyl fluoride) from ROS
homogenates and purified by Mono-Q anion exchange chromatography in a linear salt
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gradient followed by Superdex 200 gel filtration chromatography. The purified PDE6 
was concentrated by ultrafiltration, mixed with 50% glycerol and stored at -20 °C (Pentia 
et al., 2005). The catalytic activity of PDE6 was assayed with a colorimetric method 
(Cote, 2000). The PDE6 catalytic dimer (PaP) was prepared from the PDE6 holoenzyme 
by digesting the inhibitory Py subunits by a limited trypsin proteolysis as described 
previously (Hurley et al., 1982;Pentia et al., 2005). Briefly, a time course of 
trypsinization on PDE6 was performed to digest 90% of the Py subunit without altering 
the apparent molecular weight of the catalytic subunits. The PaP was purified with a 
Mono Q ion-exchange column under a linear gradient from 100 mM NaCl to 1 M NaCl 
in 10 mM Tris, pH 7.5. The PDE6 concentration was determined as described previously 
(Cote, 2000).
Isolate GARP2 from PDE6 with Hydrophobic Interaction Chromatography 
(HIC)—Purified ROS membranes were homogenized in the hypotonic buffer and the 
soluble fractions were separated from membranes by centrifugation. The hypotonic 
extraction was repeated three times. The pooled hypotonic extract was then adjusted to 
500 mM ammonium sulfate and loaded to a butyl-Sepharose column (HIC). The unbound 
proteins were washed through the column using 500 mM ammonium sulfate in 5 mM 
Tris, pH 7.5, and bound proteins were eluted by a step gradient with 400 mM, 150 mM 
and no ammonium sulfate in 5 mM Tris, pH 7.5, and 1 mM dithiothreitol. Slot blot 
analysis was used to identify GARP2-containing fractions with a GARP2 antibody as 
well as PDE6-containing fractions with PDE6 antibody. If necessary, the pooled GARP2- 
containing fractions can be loaded to the butyl-Sepharose column again to improve the
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performance. Pooled GARP2 was further purified with Mono Q ion-exchange 
chromatography.
Preparation o f GARP2-free ROS Membranes and GARP2-Jree PDE6 Using 
Triton X-100— Under dark conditions, sucrose purified ROS membranes were suspended 
and homogenized with an insulin syringe in isotonic buffer. The soluble proteins were 
removed by the centrifugation at 130,000 x g for 5 min. The ROS membranes were 
exposed to light and washed with the hypotonic buffer containing 10 mM Mg2+ (HM) to 
tightly bind PDE6 on ROS membrane. The washed ROS membranes were extracted with 
HM buffer supplied with 0.1% Triton X-100 (v/v) and spun down by centrifugation at 
130, 000 x g for 5 min. The supernatant contains most of the GARP2 and the pellet is 
GARP2-free ROS membrane with PDE6 bound to it. The ROS membrane was extracted 
with Triton X-100 three times. In order to obtain GARP2-ffee PDE6, the GARP2-free 
ROS membranes were washed with HM buffer with no detergent three times to remove 
the excess Triton X-100, followed by standard hypotonic extraction as described 
previously (Pentia, 2005). The hypotonic extract was further purified with Mono Q and 
gel filtration to achieve GARP2-free PDE6.
Purification o f Recombinant PrBP/S—The coding sequence for bovine PrBP/5 
was cloned into pET-47b (+) vector to generate (His)6-PrBP/5. Recombinant (His)6- 
PrBP/8 was expressed in E. coli BL21(DE3) cells following induction with 0.5 mM 
isopropylthiogalactoside at 37 °C for 3 hours. (His)6-PrBP/8 was purified using Ni-NTA 
affinity purification and the recombinant tag was removed by incubating with HRV3C 
protease for 16 hours at 4 °C. The bovine PrBP/5 coding sequence was also inserted to
pGEX6p vector to generate PrBP/8 with a glutathione 5-transferase (GST) fusion tag.
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GST-PrBP/8 was expressed under the same conditions as the (His)6-PrBP/8 and purified 
by affinity chromatography on a glutathione- agarose column, and the GST tag was 
removed by incubation with HRV3C protease followed by repurification of the PrBP/8 
and storage at 4 °C until use. The protein concentration of recombinant PrBP/8 was 
determined with Bradford protein assay as previously described (Bradford, 1976).
Isolation o f PDE6 from GARP2-associated ROS Membranes with PrBP/S— 
Under dark conditions, the ROS pellet was homogenized in isotonic buffer and spun 
down by centrifugation at 16,000 x g for 30 min to remove the soluble proteins. 
Meanwhile, rhodopsin spectra were examined to determine the rhodopsin concentration 
on the ROS homogenate and thereby estimate the concentration of PDE6 on ROS 
membrane. The washed ROS membranes were exposed to light and resuspended in 
isotonic buffer supplemented with 20-fold excess of recombinant PrBP/S [(His)6-PrBP/S, 
GST- PrBP/8 or PrBP/8 cleaved affinity tag] relative to PDE6. The ROS homogenate was 
incubated with PrBP/8 for 40 min at 4 °C with resuspension every 10 min using a 10 ml 
syringe to maximally increase the contact between PDE6 and PrBP/8. The homogenate 
was spun down at 16, 000 x g for 30 min to collect the soluble PDE6 from ROS 
membrane. The extraction with PrBP/8 was repeated to increase the yield of released 
PDE6. The PrBP/8 released PDE6 was further purified by Mono Q and gel filtration 
chromatography.
Separation o f PDE6 from GARP2 with Proteolysis Method—The purified ROS
membranes were homogenized in isotonic buffer in the dark followed by rhodopsin
spectrum scan to estimate PDE6 concentration. The ROS membrane was exposed to light
and resuspended with the isotonic buffer with 1 pg/ml trypsin (250 pi ROS homogenate
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with PDE6 concentration at 250 nM). The time course proteolysis was processed on ice 
to reduce the significant damage to the structure of the PDE6 catalytic dimer as well as 
the inhibitory subunits. After 30 min, 60 min and 90 min incubation, the trypsin 
proteolysis was quenched by adding 10 pg/ml soybean trypsin inhibitor (STI). The ROS 
homogenate after trypsin treatment was centrifuged at 16, 000 x g for 30 min to isolate 
the soluble fractions from ROS membrane.
Expression and Purification o f  (His)6-GARP2s and GST-GARP2—Full-length 
GARP2 and three fragments of GARP2 (amino acids 1-150, 75-225 and 151-299) were 
generated by inserting the corresponding bovine GARP2 coding sequences into the 
pET47b vector which provides an N-terminal 6xHis affinity tag. Recombinant protein 
was expressed in E. coli (DE3) Rosetta cells (EMD Lifesciences for full-length, 1-150 a.a. 
and 75-225 a.a. truncation mutats) or Arctic Express (Agilent Technology for 151-299 a.a. 
mutation) by induction with 1 mM isopropyl-P-D-thiogalactopyranoside (IPTG) at 20 °C 
for 3 hours (Rosetta cells) or at 10 °C for 18 h (Arctic Express cells). After harvesting 
two liters of cell culture by centrifugation at 8000 x g for 5 min (approximately 5 g 
pellet), cells were resuspended in 25 ml Ni-NTA binding buffer (20 mM Tris, pH 8.0,
100 mM NaCl) with EDTA-free protease inhibitor cocktail (300 pi per 5 g cell pellet). 
Cells were then lysed by 30 sonication bursts (10 sec each with 20 sec rest) on ice. After 
centrifuging the cell lysate at 16,000 x g for 50 min, the supernatant containing 
recombinant GARP2 was purified using His-Bind affinity resin. The column was washed 
with 60 mM imidazole prior to elution of His-tagged GARP2 with 250 mM imidazole.
Full-length GARP2 was also subcloned into the pGEX6Pl expression vector
(containing a GST fusion partner) and expressed in Rosetta cells after IPTG induction for
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3 hours at 20 °C. GST-GARP2 was affinity purified using immobilized glutathione beads, 
and subsequently treated with HRV3C protease to remove the fusion tag. The 
concentrations of all recombinant proteins were determined with a colorimetric protein 
assay with BSA as the standard protein (Bradford, 1976).
Immunoprecipitation Assay with ROS1 Antibody—Co-immunoprecipitation of 
GARP2 with PDE6 holoenzyme was carried out using Pierce Direct IP Kit (Thermo) and 
ROS1 antibody against bovine rod PDE6 holoenzyme(Hurwitz et al., 1984b). First,
ROS1 coupled AminoLink Plus beads were prepared per the kit instructions. Briefly, 200 
pi of the bead slurry was incubated with 200 pg of ROS 1 antibody in a modified coupling 
buffer (0.5 mM sodium phosphate, 7.5 mM sodium chloride; pH 7.2) with sodium 
cyanoborohydride supplement (3 pi sodium cyanoborohydride stock solution in each 200 
pi reaction system) at room temperature for 2 hours. The coupling reaction was quenched 
by adding 1 M Tris-HCl and the beads were washed with 1 M NaCl to remove the excess 
sodium cyanoborohydride and equilibrated with the coupling buffer before use. In the 
immunoprecipitation, 20 pi ROS 1-coupled beads were incubated with the recombinant 
GARP2 and GARP2-ffee PDE6 (500-fold molar excess GARP2 over 5 nmol PDE6 
holoenzyme) in binding buffer (20 mM Tris, pH 7.5, 100 mM NaCl, 2 mM MgCh) for 2 
hours at 4 °C. After washing the beads three times with binding buffer, the 
immunoprecipitated product was eluted with 2x gel loading buffer and subjected to SDS- 
PAGE followed by Western blot to detect the specific interaction.
Pull Down Assay—His-tagged or GST-tagged GARP2 were pre-incubated
overnight at 4 °C with Ni-NTA beads or immobilized glutathione beads, respectively.
Excess recombinant GARP2 was removed by washing the beads with binding buffer for
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three times and the washed beads were incubated with potential binding partners for 2 
hours at 4 °C by rotating the mixture. The unbound fraction and the beads were gently 
separated by centrifugation at 1000 x g for 1 min. After removing the supernatant, the 
beads were washed three times with washing buffer and proteins bound to the beads were 
eluted in 2x gel loading buffer. To control for nonspecific binding, identical samples 
were incubated with empty Ni-NTA beads or immobilized glutathione beads without 
recombinant GARP2 bound. The total loading material, bound proteins, and unbound 
proteins were subjected to SDS-PAGE followed by Western blotting to determine 
specific protein-protein interactions. In the pull-down assays using Ni-NTA beads, the 
binding buffer is 25 mM imidazole, 20 mM Tris and 100 mM NaCl, pH 8.0; the washing 
buffer is 60 mM imidazole, 20 mM Tris, 300 mM NaCl with 0.015% Triton X-100, pH 
8.0. In the pull-down assay using immobilized glutathione beads , the binding buffer 
contains 50 mM Tris and 150 mM NaCl, pH 7.5; the washing buffer contains 50 mM Tris, 
300 mM NaCl and 0.015% Triton X-100, pH 7.5.
Labeling the Recombinant GARP2 with IAF—Purified (His)6-GARP2 or GARP2 
(cleaved of the GST moiety) were concentrated, and the buffer was exchanged using 
Centricon ultrafiltration devices (Millipore # UC903024). The solution used for the 
labeling reaction was as follows: 10 mM Tris, pH 7.5, 100 mM NaCl, and 2 mM MgCb. 
Protein disulfide bonds were reduced with a 10-fold molar excess of Tris (2-carboxyethyl) 
phosphine-HCl. After the pH was adjusted to 7.5-8.0 with 100 mM Tris base, reduced 
proteins were incubated overnight at 4 °C in darkness with a 20-fold excess of 5- 
iodoacetamidofluorescein (5-IAF) suspended in DMSO. Excess label was removed by
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ultrafiltration and gel filtration chromatography as previously described. The degree of 
label incorporation was determined spectrophotometrically (Kingsbury et al., 2011).
Analytical Ultracentrifugation and Data Analysis—Experiments were performed 
in an Optima XLI analytical ultracentrifuge (Beckman-Coulter) equipped with a 
fluorescence detection system (AVIV Biomedical) (MacGregor et al., 2004). 
Sedimentation velocity studies were typically run at 50,000 rpm at 20 °C using a 
Beckman An-50 Ti rotor with double-sector cells with sapphire windows (Spin 
Analytical). Fluorescence scans (reported in arbitrary units) were acquired at 2-min 
intervals for all samples simultaneously. Analysis of 250-500 scans of each sample was 
performed according to a c(s) distribution model using the program Sedfit (Schuck et al.,
2002) to determine sedimentation coefficients of each protein or complex. Green 
fluorescent protein (GFP) (2.6 S) was used as an internal standard. The Stokes radius (RS) 
and prolate axial ratio {alb) were calculated with the program SEDNTERP (Laue et al., 
1992) using the observed sedimentation coefficient.
SDS-PAGE and Western Blotting—SDS-PAGE was performed by the method of 
Laemmli(Laemmli, 1970) in 4-12% Bis-Tris gel. The immunoblotting procedure 
followed the protocols in Gallagher (Gallagher, 1998).
Collection o f CNGB1 Protein Sequences and Multiple Sequence Alignment—Full- 
length CNGB1 vertebrate sequences (Appendix I) including the predicted protein 
sequences from genomic DNA sequencing were obtained from NCBI and Ensembl 
Genome Browser. Sequences were initially aligned using ClustalW and manually 
adjusted as needed. A phylogenetic tree was constructed from the alignment.
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Results and Discussion
Development o f the immunological approaches to characterize GARP2. GARP2
has no enzyme activity with which to track its presence and it also shows anomalous
electrophoretic mobility in which the apparent MW in SDS-PAGE is 50-60 kDa instead
of the calculated 32 kDa. The abnormal apparent MW may be caused by its high content
of negatively-charged glutamate residues which affect the distribution of SDS on GARP2
protein during SDS-PAGE. For these reasons, immunological approaches are needed to
identify and quantify GARP2. In this section, analysis was carried out with the Odyssey
Li-Cor Infrared Imaging System {see Methods). Purified rod outer segment (ROS)
membranes or purified recombinant GARP2 were subjected to SDS-PAGE and then
protein transferred to nitrocellulose for immunological detection. The major goal of this
section is to optimize the conditions for immunological detection of GARP2 using four
primary antibodies to GARP2.
Optimize the conditions for immunologic assay to detect GARP2. Most of the
conditions in each step of the immunological assay (i.e., SDS-PAGE, the transfer
procedure and antibody probing) were tested and optimized here. Considering the
abnormal migration of GARP2 in SDS-PAGE, we first tested three different SDS-PAGE
systems (4-12% Bis-Tris gel in MES or MOPS buffer; or 10-20% Tris-HCl gel in a
Tris/glycine/SDS buffer), respectively. Following SDS-PAGE and transfer proteins to the
membrane, immunoblots were processed with PDE6 and GARP2 antibodies to compare
the performance of the SDS-PAGE conditions. As shown in Fig. 2-1, PDE6 NC antibody
recognized PDE6 at -100 kDa and two forms of GARP2 (32 kDa and 45 kDa) were
detected by GARP2 FPc antibody. GARP2 was detected at 32 kDa in all three SDS-
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PAGE systems, but the signal was strongest in the MOPS buffer system. The Bis-Tris gel 
system was found to be more sensitive to GARP2 and PDE6 detection compared with the 
Tris-HCl gel system. With respect to the two different running buffers (MES and MOPS), 
which are designed for resolving different sizes of proteins in the Bis-Tris SDS-PAGE 
system, we found that the GARP2 signal at 32 kDa was comparable to the 50 kDa in the 
MOPS buffer, while GARP2 signal at 32 kDa was weaker than at 45 kDa in the MES 
buffer. Overall, the MES running buffer was found to be more sensitive for detecting 
lower levels of GARP2 and PDE6. In view of these results, we considered the 4-12% 
Bis-Tris SDS-PAGE with MES running buffer to be most suitable for GARP2 detection.
We next compared nitrocellulose and polyvinylidene difluoride (PVDF) 
membranes for immunoblot detection of GARP2 (Fig. 2-2). When equal amounts of 
GARP2 were loaded, PVDF displayed a stronger signal against GARP2 but it also 
presented much higher background than nitrocellulose did under the same conditions. We 
concluded than nitrocellulose was preferred for subsequent experiments.
We also tested 5% and 20% methanol in the transfer buffer on both kinds of 
membranes. We found that the 20% methanol transfer buffer was more effective for 
transferring GARP2 onto the nitrocellulose membrane; in contrast, no significant 
difference was detected when PVDF membranes were tested with different 
concentrations of methanol {data not shown).
After examining the conditions for transfer, the components in the blocking buffer
were also studied. Commercial Li-Cor blocking buffer, 2% BSA in Tris-buffered saline
buffer (TBS), and 5% non-fat dry milk in TBS were each incubated with nitrocellulose or
PVDF membranes. In terms of reducing the background and in the intensity of the
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4-12% Bis-Tris gel 4-12%  Bis-Tris gel 10-20%  Tris-HCl Gel
in MES buffer in M OPS buffer in Tris/glycine/SDS Buffer
Fig. 2-1. Comparison of SDS-PAGE running systems.
Three SDS-PAGE running systems (see methods) were tested with ROS 
homogenates to detect native GARP2 with a Western Blot assay. The ROS pellet 
was homogenized and washed with isotonic buffer in the dark and the 
concentration of rhodopsin in ROS was determined with a spectroscopic bleaching 
assay (Bownds et al., 1971). Homogenized ROS containing decreasing amounts of 
rhodopsin were separately loaded on each SDS-PAGE gel. After transfer of the 
proteins to nitrocellulose membrane, GARP2 FPc Ab, and PDE6 NC Ab were used 
to probe GARP2 and PDE6 in ROS. The amount of rhodopsin used was: 1: 0.75; 2: 
0.3; 3: 0.1; and 4: 0.05 nmol.





ABR 1:1000 FPc 1:3000 SP 1:1000
Fig. 2-2. Evaluation of nitrocellulose and PVDF membranes with 5% non-fat 
dry milk and 2% BSA as blocking buffer.
ROS homogenates containing 0.1 nmol rhodopsin was loaded onto each lane of 
SDS-PAGE. The proteins from SDS-PAGE gel were transferred to nitrocellulose 
(N) or PVDF (P) membranes under the same transferring conditions. Each kind of 
membrane was cut into small pieces and blocked with 5% non-fat dry milk (M) or 
2% BSA (B) in TBS buffer, respectively. For each membrane blocked with each 
blocking buffer, three GARP2 antibodies (ABR, FPc and SP) were used to detect 
GARP2. Py CT64 antibody was also applied to each membrane as the control. PM: 
PVDF with milk; PB: PVDF with BSA. NM: Nitrocellulose with milk; NB: 
Nitrocellulose with BSA.
GARP2 signal, all three different kinds of blocking buffer performed similarly (data not
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shown).
In summary, the optimal transfer conditions were determined to utilize 
nitrocellulose membranes, with 20% methanol in the transfer buffer. All of the tested 
blocking buffers did not differ in the ability to detect GARP2 on immunoblots.
Characterization o f  the different antibodies against GARP2. Four kinds of 
GAJRP2 primary antibodies (ABR, FPc, SP and 8G8) were used against different regions 
of GARP2 in this study. As shown in Fig. 2-3A, FPc antibody recognizes the entire 
GARP2 amino acid sequence. The 
ABR antibody (Thermo) is designed 
to recognize the unique C-terminus 
of GARP2 (CDVQTRVVAAGSL).
The SP antibody and 8G8 antibody 
are designed to detect the N- 
terminal sequence
(GWVQRVLPQPPGTPC) common 
to all three GARP-containing 
proteins.
As shown in Fig. 2-3B, all four antibodies detected several molecular forms of 
GARP proteins present in ROS under the optimized immunoblot conditions. However, 
each individual antibody showed different ability to recognize the different forms of 
GARP-containing proteins as well as different levels of background staining. Since 
GARP2 shares the same N-terminal region with GARP1 and CNGB1, antibodies directed





I: Antigen region : GARP2 sequence
Fig. 2-3A. Regions on GARP2 linear 
sequence recognized by the four antibodies.
FPc antibody recognizes the entire GARP2 
amino acid sequence; SP antibody and 8G8 
antibody are against the N-terminal sequence 
(GWVQRVLPQPPGTPC) on all three GARP 
proteins; ABR antibody is designed to 
recognize the unique C-terminus of GARP2 
(CDVQTRVVAAGSL).
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to this conserved region were less specific. The performance of these four primary 
antibodies is presented and summarized on Fig. 2-3B and Table 2-1.
In summary, four 
different anti-GARP2 
antibodies that recognize 
different amino acid sequences 
on GARP2 have been 
characterized. By using 
immunological analysis 
combined with the Odyssey 
Li-Cor Infrared Imaging 
System under the various 
optimized conditions, 
nanogram quantities of 
GARP2 can be detected using 
recombinant GARP2 as the' 
standard. It suggests that this 
improved immunological method can provide the best approach to assay the presence and 
the concentration of GARP2. Among these GARP2 primary antibodies, FPc antibody is 
ideal to use to detect low protein level of GARP2 because of its high sensitivity; 8G8 
antibody generated from mouse is preferred to be used in double color detection of Li- 
Cor infrared imaging system when it is needed to be combined with rabbit antibodies 












Fig. 2-3B. Characterization of four primary 
antibodies direct to GARP2.
ROS homogenates containing 0.1 nmol (1) or 
0.75 nmol (2) rhodopsin were loaded onto an 
SDS-PAGE gel. After transferring and blocking 
the nitrocellulose membranes under the same 
conditions, each GARP2 primary antibody (ABR, 
SP and 8G8 at 1000-fold dilution; FPc at 3000- 
fold dilution) was incubated with the membrane. 
The Western blot signal was obtained by Li-Cor 
scanner. Py CT64 antibody was used as control 
for first three antibodies. The circles on the figure 
indicate the presumed GARP2 signals. The 
performance of these primary antibodies is 
described in Table 2-1.
JR 1:1000 FPc 1:3000 SP 1:1000 8G8 l:10t
Table 2-1 Summary of four GARP2 primary antibodies on immunoblot
ABR FPc SP 8G8
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Development o f  methods to separate PDE6 from  GARP2. As a membrane- 
associated protein, PDE6 attaches to the ROS membrane through its hydrophobic, 
prenylated and carboxymethylated C-terminus (Catty et al., 1991). The standard 
procedures for PDE6 purification start with hypotonic extraction of PDE6 from ROS 
membranes followed by protein purification using ion exchange chromatography and gel 
filtration chromatography {see Methods). Previous work in our lab demonstrated that 
GARP2 co-purifies with PDE6 during these standard purification protocols (Pentia et al., 
2006), suggesting that GARP2 is a high-affinity PDE6 binding protein. Thus, additional 
treatment is needed to disrupt PDE6-GARP2 interactions. In this section, several methods 
have been developed to selectively separate these two proteins for further study.
High salt disrupts GARP2-PDE6 interactions and allows separation by 
hydrophobic interaction chromatography (HIC). In order to obtain purified native
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GARP2, a high concentration of ammonium sulfate is applied to disrupt the high affinity 
interaction between GARP2 and PDE6. Following the high salt treatment, the mixture of 
GARP2 and PDE6 is subjected to hydrophobic interaction chromatography (HIC). HIC 
utilizes noncovalent interactions between proteins and the hydrophobic surface of the 
HIC matrix to separate the proteins. This reversible interaction is significantly changed 
by the presence of specific concentrations of salts in the running buffer. Usually, a high 
concentration of salt enhances the interaction between proteins and HIC medium while a 
low concentration of salt causes the interaction to weaken. In HIC, the proteins with the 
lowest degree of hydrophobicity are eluted first and the most hydrophobic proteins, 
which need a greater reduction in salt concentration to reverse the interaction, elute last.
In this study, purified ROS membranes were homogenized and washed with
isotonic buffer to remove the soluble protein followed by washing the ROS membranes
in a hypotonic buffer with a high concentration of Mg2+ to bind PDE6 tightly to ROS
membrane. The complex of PDE6 and GARP2 was extracted with hypotonic buffer and
supplied with a high concentration (500 mM) of ammonium sulfate to disrupt PDE6-
GARP2 interactions. The mixture of GARP2 and PDE6 in the high salt solution was
loaded onto the hydrophobic interaction chromatography column (butyl-Sepharose). The
column was washed with a step-gradient of ammonium sulfate (500 mM, 400 mM, 150
mM and 0 mM). As shown on Fig. 2-4, it was found that 500 mM ammonium sulfate (AS)
was able to dissociate GARP2 from its binding sites on PDE6 and PDE6 was detected at
150 mM AS based on its catalytic activity, while GARP2-containing fractions were
identified in fractions lacking AS, based on Slot Blot analysis. Further purification of
PDE6 or GARP2 was performed on an anion exchange column (Mono Q). The harsh AS
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Fig. 2-4. High salt disrupts PDE6-GARP2 interactions, permitting separation 
by hydrophobic interaction chromatography (HIC).
500 mM ammonium sulfate (AS) was added to the hypotonic extract from ROS 
membranes before loading it on HIC. The profile of separation of GARP2 and 
PDE6 on HIC chromatography using Butyl-Sepharose is presented. The UV 
absorbance reading and step gradient salt concentrations are shown on y-axis and 
the elution volume is on the x-axis. After immunological detection of PDE6 as 
GARP2 in each fraction, the elution volumes of PDE6 and GARP2 were 
determined and indicated in the figure: PDE6 eluted from butyl-Sepharose at 150 
mM AS while GARP2 eluted when AS was omitted. OD280 mAU, milli-absorbance 
units.
Low concentration o f detergent can solubilize GARP2 from ROS membrane 
without releasing PDE6. We also examined whether detergent could disrupt the 
interactions between GARP2 and PDE6. During the standard PDE6 purification 
procedure, purified, disrupted ROS were first washed in isotonic buffer (IS) to remove 
the soluble proteins. The ROS membranes were then washed in 10 mM Mg2+ hypotonic 
buffer (HM) to make the rod PDE6 tightly associate with ROS membrane while releasing 
other membrane associated proteins. Finally, PDE6 was eluted from the membranes with
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hypotonic buffer lacking Mg . Usually, GARP2 is co-extracted with PDE6 under this 
hypotonic condition (Pentia et al., 2005).
In this section, we tested two detergents [CHAPS (a zwitterionic detergent) and 
Triton X-100 (a non-ionic detergent)] with an isotonic buffer. ROS homogenates were 
incubated in a series of CHAPS concentrations (3 mM, 5 mM, 10 mM, 30 mM and 50 
mM) as well as a series of Triton X-100 concentrations (0.2%, 0.3% and 1%). Following 
centrifugation, the amount of released PDE6 in each soluble fraction was determined in a 
PDE6 activity assay and the amount of GARP2 was tracked using an immunoblot assay. 
We observed that 1% Triton X-100 extracted most of GARP2 from ROS membranes, 
while -70% of the PDE6 remained membrane-bound; In contrast, CHAPS released more 
than 30% of PDE6 into the supernatant under conditions that solubilized most of GARP2 
(data not shown). For this reason, we focused subsequent efforts on Triton X-100.
In order to reduce the amount of PDE6 released with GARP2 by Triton X-100, 
we replaced the isotonic buffer with high Mg2+ buffer. As shown in Fig. 2-5, low 
concentrations of Triton X-100 (e.g., 0.1%) can solubilize all of the GARP2 from ROS 
membranes without affecting membrane attachment of PDE6 (< 10% released). This 
method confirms that the high-affinity interaction between GARP2 and PDE6 can be 
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Fig. 2-5. Low concentration of detergent selectively solubilizes GARP2 from 
ROS membranes.
Aliquots of ROS homogenate were extracted twice with the indicated concentration 
of Triton X-100 in high Mg2+ hypotonic buffer. After centrifugation soluble and 
pellet fractions were analyzed by immunoblot assay. A. GARP2 localization upon 
Triton X-100 addition. On the immunoblot, 1st extracted supernatant (IS), 2nd 
extracted supernatant (2S) and the extracted ROS membrane (M) were probed with 
GARP2 FPc and SP primary antibodies to track its location in the presence of 
Triton X-100; the circles show the GARP2 signal remaining on ROS membrane. B. 
Solubilization of PDE6 by Triton X-100. The percent of released PDE6 at each 
Triton concentration was determined with a PDE6 activity assay; the arrow 
indicates the optimized concentration of Triton.
PrBP/S binds to and solubilizes PDE6 from ROS membranes without solubilizing 
GARP2. The second approach we developed utilized the PDE6 binding protein, prenyl 
binding protein (PrBP/8) to specifically release PDE6 from the rod outer segment 
membrane. PrBP/8 comprises a single domain that serves to covalently bind prenyl 
groups attached to proteins, specifically famesyl- and geranylgeranyl-containing proteins 
(Hanzal-Bayer et al., 2002). The binding of PrBP/8 to a prenylated protein allows the 
protein to be solubilized from the membrane. In vitro, PrBP/8 has been shown to interact 
with the a and p subunits of PDE6 as well as some other phototransduction proteins
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(Florio et al., 1996) (Zhang et al., 2005a). Previous work in our lab has shown that 
recombinant (His)6-PrBP/8 interacts with PDE6 in solution and that recombinant frog 
PrBP/8 can solubilize PDE6 from frog ROS membranes (Norton et al., 2005).
In order to isolate PDE6 and GARP2, bovine PrBP/8 with a 6xHis fusion tag was 
incubated with bovine ROS homogenates at the increasing ratio of (His)6-PrBP/8 per 
PDE6 (Fig. 2-6). A PDE6 activity assay was utilized to evaluate the amount of PDE6 
released from ROS membranes and immunoblot analysis was used to track PDE6 and 
GARP2 co-localization. As shown on Fig. 2-6B, the PDE6 activity assay shows that 
greater than 90% of PDE6 was solubilized with a 20-fold molar excess of (His)6-PrBP/8 
over PDE6. This result agrees with the detected PDE6 immunological assay of the 
supernatant fraction (Fig. 2-6A). As for GARP2, no significant amount of GARP2 was 
detected by immunoblot in the soluble fraction even with a 50-fold molar excess of 
(His)6-PrBP/8 (Fig. 2-6A).
To further elucidate the specific binding of PrBP/8 to PDE6, GST-PrBP/8 and
PrBP/8 (cleaved product of GST-PrBP/S) were also compared and no significant
difference was observed under the same experimental conditions (data not shown). For
the (His)6-PrBP/8, shorter incubation times with ROS homogenates were also tested and
we found that 30 min incubation is sufficient to release more than 95% of the PDE6 from
ROS membranes at the ratio of 20 (His)6-PrBP/8 per PDE6 (data not shown). To
determine how much of the (His)6-PrBP/8 remained bound to PDE6 after solubilization,
the solubilized fraction was loaded onto Ni-NTA beads. The SDS-PAGE analysis on the
elution fraction from Ni-NTA beads suggested that (His)6-PrBP remains bound to PDE6
{data not shown). This method has been optimized to purify GARP2-free PDE6 in large
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scale (see Methods) and the yield of PDE6 is about two-fold greater that PDE6 purified 
under the standard hypotonic extraction method (Pentia et al., 2005). The purity of PDE6 
is also improved, but the high-affinity bound PrBP/5 failed to be removed from PDE6 in 
further purification including ion exchange and gel filtration. These results suggest that 
PrBP/5 can be used as a helpful tool to release PDE6 from the rod outer segment 
membrane without solubilizing GARP2 from its membrane-associated state.
Mild proteolysis treatment is used to dissociate PDE6 from ROS membrane 
without effects on GARP2. In order to avoid the potential effects of PrBP/5 binding to 
PDE6, another approach to separate PDE6 and GARP2 was evaluated that used gentle 
proteolysis. The catalytic subunits of PDE6 anchor the holoenzyme to ROS membranes 
through their prenylated, carboxymethylated C-termini (Catty et al., 1991). The 
hydrophobic C-terminal regions of a and p subunits present several trypsin cleavage sites, 
which allows trypsin digestion under mild conditions without further disrupting the 
structure of PDE6 holoenzyme. In this study, 1 pg/ml trypsin in isotonic buffer was 
incubated with ROS homogenate at 4 °C followed by quenching the protease reaction at 
each time point (30 min, 60 min and 90 min) by adding 10 pg/ml soybean trypsin 
inhibitor (STI). The ROS homogenates were spun down to separate the soluble and 
membrane fractions. An immunoblot assay with both GARP2 and PDE6 antibodies was 
performed to track the location of PDE6 and GARP2 after this treatment. As shown in 
Fig. 2-7A, increasing amounts of PDE6 were detected in the supernatant fractions upon 
longer incubation time with trypsin, but no significant amount of GARP2 was released to 
the supernatant fractions even after 90 min proteolysis treatment. The efficiency of
trypsin to release PDE6 was also determined by PDE6 activity assay. As shown on Fig.
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2-7B, the percent of total released PDE6 increased as the proteolysis incubation time 
increased, which agrees with the results of the immunoblot. In addition, there was no 
shift on the band representing the PDE6 catalytic subunit observed on the immunoblot 
before and after trypsin digestion, which indicates that this proteolytic process did not 
cause damage to catalytic subunits of PDE6. These observations suggest that a low 
concentration of trypsin for digestion is able to release PDE6 from ROS membrane 
without disrupting the membrane association of GARP2.
Because the inhibitory y subunit of PDE6 is also sensitive to trypsin and the 
trypsin digestion of Py allows PDE6 to be activated, further evaluation was required to 
test the state of PDE6 after trypsin treatment. A PDE6 activity assay for measuring non­
activated PDE6 was performed to determine the percent of non-activated PDE6 in the 
released PDE6 fractions. As presented in Fig. 2-7B, only 15% of released PDE6 was 
activated after a 90 min proteolysis (represented as triangles), which suggested that using 
this mild proteolysis condition, most of the PDE6 can be isolated from ROS membranes 
without disrupting its structure or activating it. In summary, we conclude that after 
incubation for 60 min under 4 °C at a low concentration of trypsin (1 pg/ml), ROS 
membranes are able to release 70% of PDE6 without activating it, whereas no significant 
amount of GARP2 was detected in the extracted fraction.
To summarize, several methods have been successfully developed to separate
GARP2 and PDE6, including HIC (yielding GARP2-free PDE6 and PDE6-free GARP2),
selective detergent extraction (yielding PDE6-free GARP2 and GARP2-free ROS
membranes), mild treatment with proteases (resulting in GARP2-free PDE6 and PDE6-
free ROS membranes), and use of the PDE6 binding protein, PrBP/8 (providing GARP2-
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Fig. 2-6. Prenyi binding protein 
(PrBP/8) selectively solubilizes PDE6 
but not GARP2.
Purified ROS membranes were 
homogenized and washed with isotonic 
buffer in the dark. A rhodopsin spectrum 
was used to estimate the PDE6 
concentration. ROS membranes were 
incubated with isotonic buffer 
supplemented with 10, 20 or 50 PrBP/8 per 
PDE6 (mole/mole) and the mixture 
separated by centrifugation. A. Protein 
localization upon PrBP/5 addition. Western 
blot with PDE6 NC64; GARP2 FPc and 
PrBP/8 FL antibodies were used to track 
the proteins (T: total ROS homogenate; S: 
solubilized fraction; M: extracted ROS 
membrane). B. Solubilized PDE6 as a 
function of PrBP/8 concentration. PDE6 
solubilization was quantified by an activity 
assay, normalized to the total PDE6 
activity present in the sample.
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Fig. 2-7. Mild protease treatment selectively releases PDE6 from ROS 
membranes. ROS homogenates (containing 300 nM PDE6) were incubated in an 
isotonic buffer containing trypsin for 30, 60 or 90 min, and the proteolysis reaction 
was quenched by soybean trypsin inhibitor. A. PDE6 and GARP2 localization 
during proteolysis. Western blot with PDE6 NC64 antibody was utilized to 
examing the integrity of PDE6, and GARP2 FPc was used to track the location of 
GARP2 after protease treatment (T: total ROS homogenate; S: solubilized fraction 
and M: ROS membrane). The circles indicate the released PDE6 and membrane- 
associated GARP2. B. Time course of released PDE6 from membranes during 
proteolysis. The percent of PDE6 at each time point was determined by PDE6 
activity assay. The percent of released PDE6 in the total (circles) and the percent of 
activated PDE6 in released PDE6 (triangles) indicates that this proteolysis 
condition can digest the isoprenylated C-termini anchor of PDE6 to disk 
membranes without activating it and release >70% PDE6 from membrane 
attachment while leaving GARP2 bound to ROS membranes.
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free PDE6 and PDE6-free ROS membranes). These approaches provide useful tools to 
prepare PDE6-free GARP2 and PDE6 lacking of GARP2 for work described elsewhere 
in this thesis.
Preparation and purification o f recombinant GARP2 and GARP2 fragments.
Although several separation methods were optimized in last section to isolate GARP2 
from PDE6, purification of biochemical quantities of native GARP2 from photoreceptor 
cell extracts has proven very challenging. As an alternative, expressing recombinant 
proteins generated by inserting bovine GARP2 gene into an E. coli expression vector has 
been optimized to achieve greater quantities of GARP2. In addition, inclusion of affinity 
tags on recombinant GARP2 (rGARP2) permits pull-down assays in which the protein 
with the affinity tag can be coupled to a specific resin as a bait to evaluate its interaction 
with other proteins. In this section, two affinity tags [i.e., 6xHis and glutathione S- 
transferase (GST)] were each subcloned with the bovine GARP2 gene, and the conditions 
for the expression and purification of these rGARP2 proteins were optimized.
Expression and purification o f 6xHis tagged GARP2 proteins in E. coli. A 6xHis 
tagged GARP2 (bovine GARP2 gene) was previously generated in our lab, but errors in 
the GARP2 DNA sequence were discovered during plasmid sequencing, and the protein 
product of this plasmid has not been corrected. Thus, PCR primers were redesigned and 
the bovine GARP2 gene was cloned into a pET-47b vector. The pET-47b vector was for 
rGARP2 expression because it permits affinity purification with the histidine-tagged N- 
terminus and subsequent cleavage with HRV3C protease when needed. Other proteases 
were also evaluated but we experimentally determined that all but HRV3C can degrade 
GARP2.
The pET47b-GARP2 clone was first expressed in BL21{DE3) cells, but very little 
expressed protein was detected with assay with GARP2 antibodies, even after various 
expression conditions were tested. Further study found that the predominant codons 
(CCA and CCC) for the amino acid proline in mammalian GARP2 sequence are very low 
frequency codons in the E. coli expression system. However, these 2 codons are used for 
34 of the 51 proline residues in GARP2. Additionally, another low frequency codon was 
used for 7 of the 11 arginine residues. In order to increase the expression efficiency, E. 
coli Rosetta (DE3) cells were used, because the Rosetta strain contains a plasmid that 
expresses the tRNAs for these low frequency codons, thereby enhancing the expression 
of eukaryotic proteins.
The induction conditions for 6xHis tag GARP2 expression were optimized by
varying the concentration of isopropyl (3-D-1 -thiogalactopyranoside (IPTG), the
temperature and the incubation time. IPTG at 0.2 mM, 0.5 mM and 1 mM were tested to
induce GARP2 expression and it was found that 1 mM resulted in the highest expression
level of (His)6-GARP2. It was also found that part of the expressed (His)6-GARP2 was
degraded in the intact cells induced for 3 hours at 30 °C. It is possible that the natively
unfolded GARP2 is very sensitive to proteases present in the E. coli host cell or some
special characteristics of GARP2 itself cause it to be targeted for degradation as a foreign
protein. In order to reduce the degradation of (His)6-GARP2, induction conditions for
(His)6-GARP2 expression were tested with a time course (2 hours to 18 hours) at several
temperatures (15 °C, 20 °C, 30 °C and 37 °C). Intact cells harvested for each condition
were tested for the amount of GARP2 using immunoblot assays with both GARP2
antibodies and His tag specific antibody. The results indicated that low temperatures
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(15°C or 20 °C) and shorter times of incubation (2~3 hours) were helpful in reducing the 
degradation of the protein. In the end, the optimized expression conditions used for 
(His)6-GARP2 were 1 mM IPTG at 20 G for 2 hrs.
To disrupt the bacterial cells, several conditions such as the addition of detergent 
(B-PER) in the lysate buffer, freeze/thaw cycles or sonication were evaluated before large 
scale purification. Comparison of the lysing efficiency as well as the extent of GARP2 let 
us to adopt the following cell lysis conditions: ~3 mg cell pellet, 15 cycles (10 sec 
sonication and 30 sec rest on ice) of sonication for a total of 4 min of sonication.
We optimized conditions for the Ni-NTA affinity purification method as well: 10 
mM imidazole in the binding buffer, washing the nonspecifically bound proteins with 60 
mM imidazole, and eluting (His)6-GARP2 with 250 mM imidazole. As shown in Fig. 2-8, 
Ni-NTA affinity purification results in (His)6-GARP2 (apparent MW at 50 lcDa) with 90% 
purity. The yield (-0.7 mg per liter bacterial culture) was modest compared to other 
recombinant proteins used in the lab. The purity was evaluated by SDS-PAGE and 
immunoblots with both anti-His and anti-GARP2 antibodies. We were unable to remove 
6xHis tag from the purified recombinant protein for reasons that remain unclear.
In addition to generating full-length GARP2 (299 a.a.), we created constructs of
various regions of bovine GARP2 (also inserted into the pET47b vector). The truncated
forms of GARP2 we expressed were: N-terminal region (1-150 a.a.), the central region
(75-225 a.a.) and the C-terminal region (151-299 a.a.). These (His)6-GARP2 fragments
were expressed and purified using similar conditions to those for full-length GARP2.
Similar to full-length GARP2, the apparent MW of each fragment on SDS-PAGE did not
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Fig. 2-8. Affinity purification on (His)6-GARP2.
A. Coomassie-stained SDS-PAGE on Ni-NTA affinity purification. The total cell 
lysate after sonication and the eluted, purified (His)6-GARP2 fractions were loaded 
onto SDS-PAGE followed by staining with Coomassie blue. B. Western blot to test 
purified 6xHis-GARP2. Three GARP2 primary antibodies (ABR, FPc and SP) and 
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Fig. 2-9. Affinity purification on (His)6-GARP2 fragments.
A. Coomassie-stained SDS-PAGE of affinity purified (His)6-GARP2 fragments. 
For each (His)6-GARP2 fragment, 2 pg and 5 pg purified protein were loaded on 
SDS-PAGE to evaluate their purity. NT: N-terminal (His)6-GARP2 (1-150 a.a.); 
CT: C-terminal (His)6-GARP2 (151-299 a.a.); and CENT: central (His)6-GARP2 
(75-225 a.a.). B. Western blot to evaluate purified His-GARP2 fragments. Same 
amount of different His-GARP2 proteins (1: NT (His)6-GARP2; 2: CT (His)6- 
GARP2; 3: CENT (His)6-GARP2; 4: Full-length (His)6-GARP2) were tested on 
immunoblots with GARP2 ABR, FPc, and 8G8 primary antibodies.
negatively charged amino acids found in GARP2. As shown in Fig. 2-9, N-terminal
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GARP2 was found at -27 kDa on SDS-PAGE and is recognized with GARP2 FPc and 
8G8 antibodies. The C-terminal GARP2 fragment migrates at 25 kDa and is recognized 
with GARP2 FPc and ABR antibody. The central region of GARP2 appears at —22 kDa 
on SDS-PAGE and is recognized with GARP2 FPc antibody. These three recombinant 
GARP2 fragments were expressed and purified with a yield of -0.5 mg per liter cell 
culture.
Expression and purification o f glutathione S-transferase (GST)-tagged GARP2 
proteins in E. coli. In order to improve the yield of recombinant GARP2 and eliminate 
the effect of the affinity tag on the biochemical functions of recombinant GARP2, 
another construct was generated by inserting bovine GARP2 into pGEX6p vector to 
obtain GST-tagged GARP2. The pGEX6p vector provides both the GST tag for affinity 
purification and an HRV3C cleavage site for removing the tag at the N-terminal end.
The expression level of bovine GARP2 in pGEX6p was compared between two 
host cell lines, BL21 and Rosetta, and at various ODeoo levels at the time of induction. As 
shown in Fig. 2-10, the expressed GST-GARP2 migrates at -70 kDa although its 
calculated MW is about 58 kDa. For both cell lines, the cells induced at a higher OD600 
expressed higher levels of GST-GARP2, but they also resulted in more degraded 
products. The Rosetta cell line provided more expressed protein then the standard BL21 
strain. The optimal expression conditions used Rosetta host cells and induced the cells 
when the culture reached an OD600 of 0.6. The optimized induction conditions were 
similar to (His)6-GARP2, using 1 mM IPTG for 2 hours at 20 °C.
Glutathione affinity purification (see Methods) was performed to purify GST-
GARP2, but the purity of the protein was low. As shown on the first lane on the
59
Coomassie-stained SDS-PAGE in Fig. 2-11, multiple bands under 70 kDa appeared in the 
affinity-purified GST-GARP2 sample, which indicated that the greatest percent of 
contaminating proteins should be truncated GST-GARP2 products generated during the 
expression and purification. In order to reduce the degradation level, the concentration of 
bacterial protease inhibitor cocktail was increased and some mammalian protease 
inhibitors were also added to the cell lysate buffer. However, no significant improvement 
was observed in the purified GST-GARP2 sample, so gel filtration was used to remove 
the truncated proteins. The affinity-purified GST-GARP2 was applied to a gel filtration 
column and the fractions (B5-B14) from the gel filtration purification were subjected to 
SDS-PAGE. As shown in Fig. 2-11, the fractions from B5 to B9 contained the most GST- 
GARP2 at 70 kDa, while the dominant proteins found in fractions after B9 were 
truncated products. These results suggest that gel filtration effectively purified GST- 
GARP2 (-70 kDa) from other fragments. The same fractions were also tested on 
immunoblot with both GARP2 antibody and GST tag antibody with results suggesting 
that GST-GARP2 was successfully purified by these methods and that the contamination 
from affinity purification was indeed truncated products with the GST tag, and that they 
can be successfully removed by gel filtration. The yield of purified GST-GARP2 is 1.5 
mg per liter bacterial culture, which is two-fold higher than of 6xHis tagged GARP2.
In order to cleave the GST moiety, HRV3C digestion conditions were optimized 
to be 1 unit HRV3C enzyme per 25 pg GST-GARP2 at 4 °C for 6 hours. The digested 
mixture was loaded onto glutathione beads to separate cleaved GARP2 from GST. The 
MW of purified GARP2 on SDS-PAGE is -50 kDa, similar to native GARP2 (Fig. 2-12).
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Fig. 2-10. Optimize the expression conditions for GST-GARP2.
Rosetta and BL21 stains of E.coli were induced at 0.2, 0.4, 0.6 and 1.0 OD600 for 2 
hours at 20 °C. Under each condition, the same volume of bacterial cells was lysed 
and both the intact whole cell (W) and the lysate (L) were loaded on SDS-PAGE 
followed by Western blot. GARP2 FPc antibody (red) and GST tag primary 
antibody (green) were utilized to indicate the expression level of GST-GARP2.









Fig. 2-11. GST-GARP2 purification using immobilized glutathione and gel 
filtration.
GST-GARP2 (~ 70 kDa) was expressed in Rosetta cells. Affinity purification on 
immobilized glutathione beads resulted in poor purity of the protein. The full- 
length GST-GARP2 was detected by both anti N- and C-terminal of GST-GARP2 
[anti-GST tag antibody (green color) and GARP2 ABR antibody (red color)].
1 2  3 4
- _ e' l w Fig. 2-12. GST moiety cleaved from GARP2 by HRV3C
50 kDa— protease.
Cleaved GARP2 was separated from GST with immobilized
J,luJa_| l r  W k glutathione beads. 1: GST-GARP2 before cleavage
25 kDa—  ' ' i m j j m
(~70kDa); 2: HRV3C-cleaved mixture; 3: Supernatant
(GARP2 portion); 4: GST tag bound to beads.
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In summary, we successfully purified milligram quantities of GARP2. 
Furthermore, recombinant GARP2s with two different “tags” allow them to be used in 
pull-down assays to study binding interactions with PDE6.
Characterize the biochemical and biophysical properties o f  GARP2. The ability 
to generate and purify greater quantities of recombinant GARP2 allows us to characterize 
the biochemical and biophysical properties of rGARP2 to reveal its regulatory function 
on the activity and lifetime of PDE6 in rods.
In order to study the biochemical functions o f GARP2, purified (His)6-GARP2 at
specific concentrations were incubated with PDE6 holoenzyme, fully-activated PDE6
(PaP) and transducin-activated PDE6 (Ta*-GTPyS). The concentration of (His)6-GARP2
was determined with a Bradford protein
assay with BSA as the standard protein,
and the activity of these three kinds of
PDE6 were measured in a PDE6 activity
assay. As shown in Fig. 2-13, the
presence of 100-fold molar excess (His)6-
GARP2 per PDE6 reduced PDE6 basal
activity by 40%, while the large excess of
recombinant GARP2 showed no effect on
the activity of PaP and Ta*-GTPyS
activated PDE6. The same experiment has been repeated with purified GST-GARP2 and
GARP2 after cleaving the GST tag, and similar results were obtained. This result agrees
with previous work in our lab in which the addition of exogenous native GARP2 on ROS
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Fig. 2-13. Recombinant GARP2
inhibits PDE6 holoenzyme basal
activity.
Various concentrations o f (His)6-GARP2
were incubated with 5 nM nonactivated
PDE6 (nPDE), 1 nM transducin-
activated PDE6 (taPDE), and 1 nM
trypsinized PDE6 (tPDE) to measure the
effect on PDE6 activity.
membrane only suppressed the basal activity of PDE6 holoenzyme, not the activated 
forms of PDE6 (Pentia et al., 2006). The similar suppressing effect of native and 
recombinant GARP2 on PDE6 basal activity indicates that purified recombinant GARP2 
presents similar biochemical properties to those of native GARP2.
In order to evaluate the interaction between GARP2 and PDE6, 
immunoprecipitation and pull-down assays were performed on PDE6 and recombinant 
GARP2. In the immunoprecipitation assay, ROS1, a specific antibody against PDE6 
holoenzyme, was coupled to AminoLink beads and incubated with the hypotonic extract 
from ROS membranes (positive control) or the mixture of (His)6-GARP2 and GARP2- 
free PDE6. The bound and unbound fractions were separated by centrifugation and 
loaded onto SDS-PAGE followed by an immunoblot with both GARP2 and PDE6 
antibodies. As shown on Fig. 2-14, ROS 1-coupled beads successfully 
immunoprecipitated PDE6 with its high-affinity bound native GARP2 in the ROS 
hypotonic extract sample, which agrees with a previous study (Pentia et al., 2006). 
Similarly, (His)6-GARP2 was co-immunoprecipitated by ROSl-coupled beads with 
PDE6 lacking native GARP2, which demonstrates that the recombinant GARP2 can bind 
PDE6 with high affinity.
To further test the interaction between GARP2 and PDE6, (His)6-GARP2 was
coupled to Ni-NTA beads (“bait”) followed by incubation with hypotonically purified
PDE6 holoenzyme (containing endogenous GARP2). The nonspecifically bound proteins
were washed out and the bound fractions were examined by immunoblot assay. Fig. 2-15
shows that purified PDE6 holoenzyme was detected in the (His)6-GARP2 pulled down
fraction and nonspecific binding of PDE6 was minimal on the empty control beads. A
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similar pull down assay was repeated by coupling GST-GARP2 to glutathione beads to 
pull down GARP2-free PDE6 (see Methods'). As shown in Fig. 2-15, GST-GARP2 can 
also pull down PDE6 lacking native endogenous GARP2. These results from the pull 
down assays indicate that the high-affinity interaction between GARP2 and rod PDE6 
can be reconstituted with purified PDE6 and recombinant GARP2 (6xHis tag or GST tag). 
This pull down assay with affinity-tagged GARP2 can be utilized as a tool to study the 
interacting sites between GARP2 and PDE6, and also to identify other GARP2 
interacting proteins in rod photoreceptors.
In addition to the biochemical characteristics of GARP2, the biophysical 
properties of GARP2 were determined in order to better understand the structure and 
function of GARP2. The hydrodynamic properties of GARP2 were studied with size- 
exclusion chromatography and analytical ultracentrifugation. In the core of gel filtration, 
the hydrodynamic features such as mass and shape are reflected by the elution volume of 
a protein from a size-exclusion column. We used purified GARP2 (GST-GARP2 lacking 
GST tag) and loaded it onto a size-exclusion column. GARP2 eluted at volumes 
suggesting an apparent MW of 200~250 kDa (data not shown), much larger than 
predicted by its amino acid sequence (32 kDa). This observation indicates that GARP2 
may be present in an oligomeric state under those conditions or that GARP2 has a 
hydrodynamic radius much larger than that of a typical globular protein of this MW.
In order to examine whether GARP2 exists in an oligomeric state, sedimentation
velocity analysis of GARP2 was performed. Sedimentation velocity measures the rate at
which molecules move in response to centrifugal force to provide hydrodynamic
information (size, shape and interactions of macromolecules) in solution. Purified (HisV
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GARP2 or GARP2 moiety from GST-GARP2 was first labeled with 5- 
iodoacetoimidofluorescein (5-LAF) and free 5-LAF dye was removed by gel filtration. As 
shown on Fig. 2-16A, (His)6-GARP2 has a peak at ~1.3 S and multiple peaks at higher S 
values (3.5 S-6.5 S), suggesting that (His)6-GARP2 exists in a monomer-multimer 
equilibrium state. In contrast, only one peak at 1.6 S was detected for GARP2 in which 
the GST tag has been removed (Fig. 2-16B). The different sedimentation velocity profiles 
between (His)6-GARP2 and GARP2 indicated that the oligomeric state of (His)e-GARP2 
may be caused by the affinity tag instead of the GARP2 protein itself. The S value of 
GARP2 protein at 1.6 S corresponds to Stokes radius of 46 A, which means that GARP2 
is a natively unfolded protein, unlikely to have significant secondary or tertiary structure.
To summarize, the biochemical properties of recombinant GARP2s were 
evaluated by a PDE6 activity assay and a pull-down assay. The results suggest that they 
have similar properties to native GARP2 including suppressing the basal activity of 
PDE6 and binding to PDE6 with high affinity. Analytical ultracentrifugation also 







Fig. 2-14. Using PDE6 ROS1 antibody to 
immuneprecipitate GARP2.
The ROS1 antibody was incubated with a mixture 
of His-GARP2 and a PDE6 holoenzyme lacking 
endogenous GARP2 (GF-PDE6). ROS1 beads 
were also similarly incubated with the hypotonic 
extract from ROS membrane (ROS Hypo). The 
total mixture (L), unbound fraction (U) and 
immunoprecipitated fraction (B) were tested in a 
Western blot assay using PDE6 NC64 antibody 
and GARP2 FPc antibody.
A.
Empty beads (His)A-GARP2 
L U B U B
PDEa/p 
Py
„  GST-GARP2 _  „ , ,B. , , Empty beadsbeads
PDE6
GST-GARP2
Fig. 2-15. Using recombinant GARP2 to pull 
down PDE6. A. 1 nM PDE6 was mixed with 
20 (iM (His)6-GARP2 immobilized on Ni-NTA 
beads. PDE6 NC64 antibody and Py CT97 
antibody were used to detect PDE6 holoenzyme 
in Western blot assay. B. PDE6 NC64 antibody 
and GARP2 8G8 antibody were used in a 
Western blot assay in order to detect binding of 
PDE6 to immobilized GST-GARP2. Empty 
beads lacking recombinant GARP2 were used 
to evaluate the nonspecific binding to the beads. 
L: total loading sample; U: unbound fraction;
B: beads pulled-down fractions.
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Fig. 2-16. Sedimentation velocity of GARP2/5-IAF.
A. 10, 30 and 100 nM (His)6-GARP2 labeled with 5-IAF dye were tested in AU- 
FDS at 60,000 RPM with 500 scan (1 min/scan). It has its first peak at -1.3 S and 
multiple peaks at higher S values. B. 30 nM and 100 nM GARP2 was labeled with 
5-IAF and applied to AU-FDS. Only one single peak presents as GARP2 at 1.6 S, 
which corresponds to Stokes radius of 46 A. AU-FDS performed and analyzed by 
Sue Matte.
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Phylogenetic analysis o f  CNGB1 gene and alternative splice products. The P
subunit of the cGMP-gated channel gene in rod photoreceptors (CNGB1) is a member of 
the cyclic nucleotide-gated channel (CNG) gene family. In humans, there are six CNG 
gene members including four a subunits and two p subunits (Kaupp et al., 2002). CNGA1 
and CNGB1 are expressed in rod photoreceptors, while CNGA3 and CNGB3 are 
expressed in cone photoreceptors. In addition to photoreceptors, other cell types also 
express CNG subunits, for example, CNGA2 is functional in olfactory sensory neurons 
and CNGA4 in taste receptor cells (Nordstrom et al., 2004).
In mammalian rod photoreceptors, the cyclic nucleotide gated channel consists of 
three a  subunits (CNGA1) and one p (CNGB1) subunit (Shuart et al., 2011). The 
molecular characterization of CNGB1 in bovine, human and mouse indicated that 
CNGB1 presents an unusual bipartite structure, in which the N-terminal portion of 
CNGB1 is a glutamic acid-rich (GARP) region and the C-terminal region is the channel­
like domain responsible for the cGMP regulated ion gating function (Korschen et al., 
1995;Ardell et al., 1995;Colville et al., 1996;Colville et al., 1996). In addition to the 
GARP region on the N-terminal portion of CNGB1, there are also two soluble forms of 
glutamic acid-rich protein, GARP1 and GARP2, found in rods and they are determined to 
be the alternative splice products of the CNGB1 gene (Sugimoto et al., 1991). A genomic 
study on CNGB1 gene in Dr. Pittler’s lab has mapped the CNGB1 locus encoding the 
GARP and CNGB1 transcripts to human chromosome 16ql3 region and along with 
determining the gene structure of the human CNGB1 (Ardell et al., 2000). The human 
CNGB1 gene (-100 kb) consists of 33 exons including the GARP exons (1-16 exons) and
the channel-like exons (17-33 exons). The transcript of the P subunit of the channel is
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encoded by 1-33 exons; the GAJRP2 transcript is encoded by exon 1-12 with an additional 
12a exon. While the GARP1 transcript is encoded by exon 1-16 and one alternative 
splicing exon P4b excluding exon 12a (Ardell et al., 2000). The presence of multiple 
alternative splicing products of CNGB1 gene suggests that CNGB1 gene is complex and 
its alternative splice products may have multiple roles in rod photoreceptors.
In order to better understand the GARP proteins, we did genomic analysis of the 
CNGB1 gene from multiple vertebrate species, and found CNGB1 orthologs in most 
vertebrate species including mammalians, birds and fishes. To examine GARP2 
specificity, both human and bovine GARP2 mRNA sequences were used as a query to 
blast other database to characterize the occurrence of GARP2 in other species. However, 
no other species were found to have GARP2 gene products except for cow, human and 
mouse.
A multiple sequence alignment of CNGB 1 proteins across vertebrate evolution 
was performed. A list of the species in which CNGB1 or GARP proteins were found is 
presented in Appendix I. The alignment suggests that mammals have longer CNGB1 
amino acid sequences compared with amphibian and fish. In these organisms, the N- 
terminal one third of the mammalian amino acid sequence is missing. The multiple 
sequence alignment reveals that several conserved regions in the sequence of CNGB1, 
including the major portion of the calmodulin binding domain (567-599 a.a.), a part of 
transmembrane domain (655-769 a.a, 789-985 a.a.) and the whole region of cGMP 
binding domain (789-1083 a.a.). The phylogenetic tree of CNGB1 is shown in Fig. 2-17 
suggesting that CNGB 1 evolution follows expectations based on accepted evolutionary 
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Fig. 2-17. Phylogenetic tree of vertebrate CNGB1.
The accession numbers and source of the CNGB1 sequences used in this study are 
listed on Appendix I.
Because GARP1 and GARP2 are only observed in three species (human, cow and 
mouse), we repeated our multiple sequence alignment on the N-terminal region of 
CNGB1 (a.a. 1-370 of human) to seek genomic evidence for the presence of GARP-like 
proteins in other species. In mammals, the N-terminal region appears variable, with some
limited blocks of amino acid residues that appear more highly conserved. As seen in the 
Fig. 2-18, the first 20 amino acid are highly conserved and a.a. 267-272 is also conserved. 
A phylogenetic tree of the N-terminal 370 a.a. is shown in Fig. 2-19. These results 
suggest that the N-terminal region of CNGB1 has some stretches of amino acids that are 
under selective pressure, whereas most of the region appears variable.
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Fig. 2-18. The sequence alignment for GARP2 region of vertebrate CNGB1, 
using bovine sequence as the reference. A multiple sequence alignment of the N- 
terminal region of CNGB1 (a.a 1-371 of the human CNGB1 sequence) (shown in 
Appendix II). The accession numbers and source of the CNGB1 sequences used in 
this study are listed on Appendix I. Red represents unanimous sites, while blue 
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Fig. 2-19. Phylogenetic tree of the N-terminal region of vertebrate CNGB1.
The multiple sequence alignment is shown in Appendix II. The accession numbers 
and source of the CNGB1 sequences used in this study were listed on Appendix I.
Summary
To summarize, using improved immunological methods with different primary 
antibodies, we are able to characterize and localize GARP2. We also improved several 
approaches to isolate PDE6 from its high-affmity bound GARP2 to prepare GARP2-free 
PDE6 and GARP2 lacking PDE6. In addition, recombinant GARP2 was constructed as a 
fusion protein with 6xHis or GST tag. Our initial work suggests that recombinant GARP2
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behaves similarly to native GARP2. The multiple sequence aliments of CNGB1 and the 
N-terminal region of CNGB1 in vertebrate species also suggests that the GARP region 




REGULATION OF THE CATALYTIC AND ALLOSTERIC 
PROPERTIES OF PHOTORECEPTOR PHOSPHODIESTERASE 
(PDE6) BY THE GLUTAMIC ACID-RICH PROTEIN-2 (GARP2)
Abstract
As the central effector of the visual signaling pathway in photoreceptor cells,
photoreceptor phosphodiesterase (PDE6) is precisely regulated to control the sensitivity,
amplitude, and lifetime of the light response. The aim of this study is to define the
regulatory significance of the Glutamic Acid-Rich Protein-2 (GARP2) on PDE6 during
phototransduction. GARP2 is a splice variant of the rod photoreceptor cGMP-gated
channel p-subunit which is abundant in the outer segment of rod photoreceptors and
interacts with several photoreceptor proteins. Previous work demonstrated that GARP2 is
an intrinsically disordered protein that binds PDE6 and lowers its catalytic activity when
PDE6 is not light-activated. In this study, we identified the inhibitory y-subunit (Py) of
PDE6 as the primary site of interaction with GARP2. Using a series of Py truncation
mutants, we localized the primary site of GARP2 interaction to the N-terminal region of
Py. The C-terminal region of GARP2 had the greatest influence on suppressing PDE6
basal activity. Binding of GARP2 to PDE6 holoenzyme also lowered cGMP binding to
allosteric binding sites on PDE6. Finally, we determined that GARP2 decreased the
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maximum extent to which the photoreceptor G-protein, transducin, can activate PDE6. 
Together, these results are consistent with a role for GARP2 in both lowering PDE6 basal 
activity to reduce “dark noise” as well as in reducing the efficiency of transducin 
activation of PDE6 during photoresponse saturation of rod photoreceptors.
Introduction
Cyclic GMP (cGMP) is the primary intracellular messenger for the visual 
transduction cascade in retinal rod and cone photoreceptor cells. Light stimulation causes 
the photoisomerization of the visual pigment molecule (opsin) in the outer segment of rod 
and cone photoreceptor cells; each photoexcited opsin can activate over one hundred 
heterotrimeric G-proteins (transducin). Activated transducin, in turn, binds to and 
activates a cyclic nucleotide phosphodiesterase (PDE6) by displacing its y-inhibitory 
subunit from the catalytic pocket and accelerating the hydrolysis of cGMP. As a result of 
PDE6 activation, cGMP levels in the photoreceptor fall rapidly, causing the closure of 
cGMP-gated ion channels in the plasma membrane of photoreceptor cells. The transient 
hyperpolarization of the cell membrane that results from this enzyme cascade generates 
the electrical response that is propagated to other retinal neurons (Arshavsky et al., 2012).
As the central effector enzyme of visual transduction, PDE6 must be precisely
regulated to control the sensitivity, amplitude and kinetics of the photoresponse during
excitation, termination and adaptation to light stimulation. The PDE6 holoenzyme
consists of a catalytic heterodimer (PaP) and two inhibitory y-subunits (Py). Py is a 9.7
kDa protein which contains multiple sites of interaction with Pap to allosterically
regulate the activated lifetime of PDE6 during phototransduction (Cote, 2006;Guo et al.,
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2008). Previous studies have found that Py directly regulates the rate of cGMP hydrolysis 
by binding of its C-terminal residues to the enzyme active site (Granovsky et al., 1997). 
The central, polycationic region of Py serves an allosteric role in modulating cGMP 
binding to noncatalytic regulatory sites located in the GAFa domain of each catalytic 
subunit (Mou et al., 2001;Zhang et al., 2012). Additional sites of interaction of Py with 
Pap have been reported to allosterically inhibit cGMP hydrolysis by a mechanism which 
is distinct from Py binding directly to the active site (Zhang et al., 2010a). Py also has 
multiple sites of interaction with activated transducin a-subunit (Ta*-GTP) and the 
regulator of G-protein signaling 9-1 (RGS9-1) that mediate both the excitation and 
inactivation phases of PDE6 regulation during visual transduction (Slep et al., 2001;Guo 
et al., 2010;Zhang et al., 2012). In spite of this knowledge, there are aspects of the 
photoresponse that cannot be accounted for by established mechanisms, and hence other 
regulatory mechanisms are likely to also contribute to modulation of PDE6 activation and 
inactivation during phototransduction (Fain, 2011).
One candidate that may provide additional regulatory control of PDE6 is the
Glutamic Acid-Rich Protein-2 (GARP2), a 299 amino acid splice variant of the P-subunit
of the rod cyclic nucleotide-gated ion channel (CNGB1); a longer (590 a.a) splice variant
GARP1, has also been identified (Colville et al., 1996). GARP2 is expressed exclusively
in rod photoreceptor cells and localizes to the signal-transducing outer segment portion of
the cell (Korschen et al., 1999). GARP2 is considered a natively unfolded protein
exhibiting a large degree of intrinsic disorder (Batra-Safferling et al., 2006). GARP2
interacts with several phototransduction proteins including PDE6 and peripherin
(Korschen et al., 1999;Poetsch et al., 2001;Pentia et al., 2006). GAJRPs may also play a
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role in buffering Ca2+ concentration in rods (HaberPohlmeier et al., 2007) and act as a 
gating inhibitor of CNG channels to reduce the current noise from the CNG channels in 
the absence of cGMP (Michalakis et al., 2011).
The physiological role of GARP splice variants of the P-subunit of the cyclic 
nucleotide-gated channel has been investigated using transgenic animals in which the 
CNGB1 gene has been manipulated. Deletion of exon 26 of the mouse CNGB1 gene 
(Cngbl-X26) resulted in loss of expression of the channel portion of CNGB1 without loss 
of expression of the GARP1/2 region; Cngbl-X26 mice exhibited shortened rod outer 
segments (ROS) but normal morphological organization of disk membranes (Huttl et al., 
2005). In contrast, complete ablation of the CNGB1 gene (Cngbl-Xl) where neither the 
GARP 1/2 domain nor the channel domain was expressed resulted in shortened ROS and 
misaligned and misshapen disks (Zhang et al., 2009). The light sensitivity and response 
amplitude in rods of both Cngbl-X26 and Cngbl-Xl mice were greatly reduced or 
abolished (Huttl et al., 2005;Zhang et al., 2009). In addition, overexpression of GARP2 in 
transgenic mouse rods significantly increased phototransduction gain and delayed the 
photoresponse recovery time (McKeon et al., 2012).
The role of GARP2 may reflect one or more of the physiological differences
between rods and cones. For example, rods exhibit much greater light sensitivity than
cones (Korenbrot, 2012), attributed in part to the lower level of “dark noise” that allows
rods to achieve single photon sensitivity (Baylor et al., 1980;Rieke et al., 1996;Rieke et
al., 2000). The smaller, continuous component of dark noise in rods has been attributed to
spontaneous activation of PDE6 independent of transducin (Rieke et al., 1996)]. A
second physiological difference between rods and cones is that the rod photoresponse
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saturates in bright light, but cones do not (Korenbrot, 2012). Since the maintenance of the 
circulating ion current and the activity of phototransduction enzymes are major energy- 
requiring pathways in photoreceptors (Okawa et al., 2008), it is reasonable that rod- 
specific mechanisms exists to reduce cGMP metabolic flux to conserve metabolic energy 
during rod photoresponse saturation.
In this paper, we demonstrate that GARP2 primarily interacts with the inhibitory y 
subunit of PDE6, with the N-terminal half of Py showing the high affinity for GARP2.
We show that GARP2 influences PDE6 in three distinct ways: (1) suppresses basal 
activity of PDE6, an effect localized to the C-terminal portion of GARP2; (2) destabilizes 
cGMP binding to PDE6 GAF domains, and; (3) reduces the extent to which transducin 
activates PDE6. The ability of GARP2 to influence both the allosteric and catalytic 
properties of PDE6 suggests that GARP2 regulates PDE6 activity and lifetime through 
multiple interacting sites with the rod PDE6 holoenzyme. GARP2 may be responsible for 
maintaining lower levels of dark noise characteristic of rod photoreceptors, as well as 
reducing cGMP metabolic flux (and thus ATP consumption) under bright light conditions 
where the rod photoresponse is saturated.
Materials and Methods
Reagents—Mouse monoclonal anti-GARP2 antibody (8G8) to the first 15 amino
acid of GARP2 was a generous gift from Dr. Robert Molday (University of British
Columbia). Rabbit polyclonal anti-GARP antibodies to bovine sequences common to
GARP1, GARP2 and the rod p-subunit CNGB1 was a kind gift o f Dr. Benjamin Kaupp
(Center of Advanced European Studies and Research, Bonn, Germany). The ROS1
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mouse monoclonal antibody (Hurwitz et al., 1984a) directed against the PDE6 
holoenzyme was kindly provided by Dr. Rich Hurwitz (Baylor College of Medicine). 
Affinity-purified anti-peptide rabbit polyclonal antibodies directed to the PDE6 GAFb 
domain (NC397-64), the C-terminus of the Py-subunit of PDE6 (CT-9710) and to the 
central region of Py-subunit of PDE6 (CENT-9712) were prepared in our laboratory. The 
Ni2+-nitriloacetic acid (NTA) His-Bind resin was obtained from Novagen, and 
glutathione-agarose was from Thermo-Fisher/Pierce. Phospholipids were purchased from 
Avanti Polar Lipids, Inc. All other reagents were from Sigma Chemical Co. or from 
Thermo-Fisher.
Preparation o f  Bovine Rod Outer Segments (ROS)—ROS from frozen bovine 
retina (W. L. Lawson, Inc.) were prepared as described previously (Pentia et al., 2005). 
Briefly, ROS were isolated from frozen bovine retinas on a discontinuous sucrose 
gradient. ROS membranes were isolated by homogenizing ROS in an isotonic buffer (10 
mM Tris, pH 7.5, 60 mM KC1, 40 mM NaCl, 2 mM MgCL, 1 mM dithiothreitol, 0.3 mM 
phenylmethylsulfonyl fluoride) using a glass, hand-held homogenizer, and the ROS 
membranes were separated from the soluble protein fraction by centrifugation.
Purification and Functional Assays o f PDE6 Holoenzyme and Catalytic Dimer 
(Paf)—PDE6 holoenzyme was purified by successive steps of protein extraction from 
ROS membranes, anion exchange chromatography, and gel filtration chromatography as 
described previously (Pentia et al., 2005). PaP catalytic dimer lacking Py were prepared 
from purified PDE6 holoenzyme by limited trypsin proteolysis followed by Mono Q 
anion exchange chromatography (Pentia et al., 2005).
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Two methods were used to purify PDE6 holoenzyme lacking bound GARP2. The 
first approach relied on the ability of 0.1% Triton X-100 to selectively extract GARP2 
from ROS membranes. ROS membranes (depleted of soluble proteins) were resuspended 
in a solution containing 0.1% (v/v) Triton X-100, 5 mM Tris, 10 mM MgCb, 1 mM 
EDTA, 1 mM DTT, and 0.3 mM PMSF at pH 7.5, and the detergent-solubilized proteins 
were separated by centrifugation; this process was repeated three times. Subsequently, 
GARP2-depleted PDE6 was extracted from the membranes in the same hypotonic buffer 
lacking MgCl2 and Triton X-100. The second method used the prenyl binding protein/8 
[PrBP/8; (Goc et al., 2010)] to selectively extract PDE6 holoenzyme free of GARP2 from 
ROS membranes. Briefly, washed ROS membranes were resuspended in isotonic buffer 
containing a 20-fold molar excess of recombinant PrBP/8 per PDE6 holoenzyme. After 
40 min incubation at 4 °C, the solubilized PrBP/8-PDE6 complex was separated by 
centrifugation. PDE6 was subsequently purified by Mono Q and gel filtration 
chromatography.
The catalytic activity of PDE6 was measured using a colorimetric assay (Cote, 
2000). The PDE6 concentration was estimated based on the rate of cGMP hydrolysis of 
trypsin-activated PDE6 and the knowledge of the kcat of the enzyme [5600 mol cGMP 
hydrolyzed per mol Pap per second (Mou et al., 1999)].
The equilibrium and kinetic properties of [3H]cGMP binding to PaP were
determined with a filter binding assay (Cote, 2005). To minimize catalytic activity, PaP
was preincubated with 10 mM EDTA, 20 mM dipicolinic acid and 100 pM vardenafil in
binding buffer (100 mM Tris, 2 mM MgCb, and 0.5 mg/ml bovine serum albumin) for 2
h at 22 °C. PaP was then reconstituted with Py and incubated with the indicated
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concentrations of [3H]cGMP for 5 min at room temperature; portions were directly 
filtered on prewet nitrocellulose membranes (Millipore HA membrane, 0.45 mm) and 
quickly rinsed with three 1 ml portions of 100 mM Tris (pH 7.5). Nonspecific binding 
was determined as described previously.
Expression and Purification o f (His)e-GARP2 and GST-GARP2—Full-length 
bovine GARP2 (NP 001129113) and three fragments of GARP2 (amino acids 1-150, 75- 
225, and 151-299) were generated by sub-cloning the GARP2 gene into the pET47b 
vector which contains an N-terminal (His)6 tag. Recombinant protein was expressed in E. 
coli (DE3) Rosetta cells (EMD Lifesciences) or Arctic Express cells (Agilent Technology) 
by induction with 1 mM isopropyl-p-D-thiogalactopyranoside (IPTG) at 20 °C for 3 
hours or at 10 °C for 18 h. After lysing the cells by sonication followed by centrifugation, 
proteins in the supernatant were purified using His-Bind affinity resin. The column was 
washed with 60 mM imidazole prior to elution of His-tagged GARP2 with 250 mM 
imidazole. Full-length GARP2 was also subcloned into the pGEX-6P-l expression vector 
(containing a GST fusion partner) and expressed in Rosetta cells after IPTG induction for 
3 h at 20 °C. GST-GARP2 was affinity purified using immobilized glutathione beads, and 
subsequently treated with HRV3C protease to remove the fusion tag. The concentrations 
of all recombinant proteins were determined with a colorimetric protein assay (Bradford, 
1976).
Expression and Purification o f Py Mutants—Wild-type and mutant Py were
generated and purified by SP Sepharose chromatography, followed by C4 reverse-phase
high pressure liquid chromatography as described previously (Zhang et al., 2012). The
purity (> 95%) and molecular weight of these proteins were confirmed by sodium
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dodecyl sulfate-polyacrylamide gel electrophoresis. Protein concentrations were 
determined by the bicinchoninic acid protein assay using bovine y-globulin as a standard.
Pull Down Assays—6xHis-tagged or GST-tagged proteins were pre-incubated 
overnight at 4 °C with Ni-NTA beads or immobilized glutathione beads, respectively. 
Excess protein was removed and the washed beads were incubated with potential binding 
partners for 2 h at 4 °C. Following centrifugation, the beads were washed three times and 
proteins bound to the beads were eluted in 2x gel loading buffer. To control for 
nonspecific binding, identical samples were incubated with Ni-NTA beads or 
immobilized glutathione beads lacking “bait.” The total loading material, bound proteins, 
and unbound proteins were subjected to SDS-PAGE followed by Western blotting to 
determine specific protein-protein interactions. For pull-down assays using Ni-NTA 
beads, the binding buffer contained 25 mM imidazole, 20 mM Tris and 100 mM NaCl, 
pH 8.0 ; the washing buffer contained 60 mM imidazole, 20 mM Tris, 300 mM NaCl with 
0.015% Triton X-100, pH 8.0. For the pull-down assay using immobilized glutathione 
beads, the binding buffer contained 50 mM Tris, 150 mM NaCl, pH 7.5; the washing 
buffer contained 50 mM Tris, 300 mM NaCl and 0.015% Triton X-100, pH 7.5.
Immunoprecipitation Assay o f the PDE6-GARP2 Interaction with ROS1
Antibody—The ROS1 antibody was coupled to AminoLink Plus coupling resin using
Pierce Direct IP Kit (Thermo). For each reaction, 20 pi ROS 1-coupled beads were
incubated with recombinant GARP2 and GARP2-free PDE6 (500-fold molar excess
GARP2 over PDE6 holoenzyme) in binding buffer (20 mM Tris, 100 mM NaCl, 2 mM
MgC^.pH 7.5) for 2 hours at 4 °C. After washing the beads three times with binding
buffer, the immunoprecipitate was eluted with sample buffer and subjected to SDS-
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PAGE and detected by immunoblot analysis using PDE6 NC antibody and GARP2 8G8 
antibody.
SDS-PAGE and Western Blotting and Protein Quantification —SDS-PAGE was 
performed with NuPAGE 4-12% Bis-Tris gels. For the immunoblot procedure, proteins 
were transferred to a nitrocellulose membrane at 60 V for 2 h. The membranes were 
blocked in 5% non-fat milk in TBS buffer (50 mM Tris, 138 mM NaCl, 2.7 mM KC1, pH 
7.5) for 2 hours followed by incubation in primary antibody solutions overnight at room 
temperature. After rinsing the membranes with TBS/0.05% Tween-20, the membranes 
were incubated with the appropriate IRDye secondary antibodies (Li-Cor) for 1 hour 
prior to scanning the membrane.
The intensity of individual bands of GARP2 and PDE6 on Coomassie-stained 
SDS-PAGE were determined using the Li-Cor imaging system software. To quantify 
GARP2 and PDE6, the intensity of GARP2 or PDE6 bands was referenced to a set of 
protein standards whose concentration was determined by either the Bradford protein 
assay (GARP2 and PDE6) or enzymatic activity (PDE6).
Formation o f Large Unilamellar Vesicles (LUVs)—LUVs were utilized to 
improve the efficiency of transducin activation of PDE6 (Melia et al., 2000), following an 
established procedure (Wensel et al., 2005). Briefly, the l,2-dioleoyl-5«-glycero-3- 
phosphocholine (DOPC) and l,2-dioleoyl-3-trimethylammonium-propane (DOTAP) 
were mixed at molar ratio of 80:20 in chloroform, evaporated, and resuspended in a 
buffer containing 20 mM HEPES, 120 mM NaCl, 5 mM MgCL, pH 7.5. After five 
ffeeze-thaw cycles, the LUVs were formed by extruding the lipid solution ten times
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through a 0.1 pM polycarbonate membrane using a Mini-Extruder (Avanti Polar Lipids, 
Inc.).
Purification o f  Persistently Activated Transducin a-subunit—Transducin a- 
subunit was extracted from the PDE6-depleted ROS membranes by addition of 50 pM 
GTPyS in low salt buffer (5 mM Tris, 0.5 mM MgCL, pH 7.2). The extracted Ta*- 
GTPyS solution was purified by Blue-Sepharose column chromatography (Wensel et al.,
2005) followed by gel filtration chromatography to completely remove PDE6.
Data Analysis—All experiments were repeated at least three times, and averages 
are reported as the mean ± S.D. Curve fitting was performed using Sigmaplot (SPSS, 
Inc.). Statistical analysis of cGMP binding experiments was evaluated using one-way 
ANOVA in conjunction with Tukey’s test. Significance was defined as p < 0.05.
Results and Discussion
GARP2 primarily binds to the PDE6 holoenzyme through interactions with the
inhibitory subunit, Py. Previous work in our lab demonstrated that GARP2 binds PDE6
with high-affinity, as judged by co-purification of PDE6 with GARP2 through several
stages of purification (Pentia et al., 2006). To better understand how GARP2 binds to and
regulates PDE6, we developed protocols to isolate and purify PDE6 holoenzyme lacking
bound GARP2 {see Methods). Using purified, GARP2-free PDE6 holoenzyme, we
performed pull-down experiments with recombinant, (His)6-GARP2 immobilized on Ni-
NTA beads. We found that GARP-free PDE6 holoenzyme interacted with the
immobilized GARP2 and was pulled down (Fig. 3-1 A). We also confirmed the ability of
exogenous GARP2 to be immunoprecipitated in a complex with PDE6 holoenzyme using
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the R0S1 antibody which recognizes the PDE6 holoenzyme [(Hurwitz et al., 1984b); 
data not shown].
We next addressed the question of the binding stoichiometry of GARP2 to the 
purified, heterotetrameric PDE6 holoenzyme. To quantify GARP2 bound to PDE6, we 
used recombinant GARP2 as a protein standard on Coomassie-stained SDS-PAGE. PDE6 ,





Fig. 3-1. Interaction of GARP2 with PDE6 subunits. A. GARP2 interacts with 
PDE6 holoenzyme and Py but not Pa(3. His-GARP2 (2 nmol) pre-adsorbed to 20 pi 
Ni-NTA beads were incubated with 5 pmol purified PDE6 holoenzyme (PaPyy), 5 
pmol catalytic dimer (PaP), or 10 pmol Py. Equivalent amounts of initial protein 
sample (“T”), proteins bound to Ni-NTA beads (“B”), and proteins nonspecifically 
bound to control beads (lacking His-GARP2; “C”) were loaded to SDS-PAGE. 
Proteins were detected by immunoblot analysis using PDE6 catalytic subunit 
antibody (NC397-64), GARP2 antibody (8G8), or Py antibody (CT9710). B. 
GARP2 forms a stable complex with immobilized Py. His-Py (0.5 nmol) was bound 
to 20 pi Ni-NTA beads and then mixed with either GARP2 (1 nmol) or with known 
Py-interacting proteins: PaPyy (5 pmol), PaP (5 pmol) or Ta*-GTPyS (1 nmol). 
Samples bound to the Ni-NTA-Py beads (“B”) were separated from unbound 
protein (“U”), and control samples (lacking His-Py bait) were also tested (“C”).
was quantified by both activity measurements and the Bradford assay after correcting for
the purity of the PDE6 (as determined with Coomassie-stained gels. In this way, the
measured stoichiometry of GARP2 bound to purified PDE6 holoenzyme was 1.0 ± 0.2
mol GARP2/mol PDE6 (n = 3).
We next asked which subunits of the PDE6 holoenzyme are responsible for
interacting with GARP2. Using (His)6-GARP2 immobilized on Ni-NTA beads as “bait”,
we performed pull down assays on purified PDE6 holoenzyme, catalytic dimer (PaP),
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and Py. As shown in Fig. 3-1 A, GARP2 interacted with PDE6 holoenzyme and with Py, 
whereas no significant association could be detected with the PaP catalytic dimer. We 
confirmed the specificity of GARP2 interaction with Py by using (His)e-Py as the bait to 
pull down recombinant GARP2 (lacking the 6xHis tag) as well as other known Py- 
interacting proteins (i.e., PDE6 holoenzyme, Pap, and activated transducin a-subunit, 
Ta*-GTPyS; Fig. 3-1B). We conclude that GARP2 forms high affinity interactions 
primarily with the inhibitory Py subunit, regardless of whether Py is associated with 
PDE6.
The N-terminal ha lf o f  Py is the major interacting region between Py and 
GARP2. Having identified Py as the major interacting subunit for GARP2 binding to 
PDE6, we next sought to define the region(s) of Py responsible for stabilizing GARP2 
binding. The 87-amino acid Py of rod photoreceptors consists of multiple sites of 
interaction along its entire length with PDE6 catalytic subunits, transducin a-subunit, 
RGS9-1, as well as serving as a substrate for post-translational modifications, all of 
which are proposed to regulate PDE6 activity during various stages of phototransduction 
(Guo et al., 2008). Knowing the sites of interaction of GARP2 with Py may provide 
insight into the regulatory role of GARP2 binding to PDE6.
To localize the regions on Py that bind to GARP2, we created a set of GST-tagged
truncation mutants of Py to determine which mutants could stably interact with GARP2
in pull-down assays. Following addition of GARP2 to various Py truncation mutants that
were immobilized on glutathione-agarose beads, we assayed the ability of the Py mutants
to stably bind GARP2 in pull-down assays. As seen in Fig. 3-2A, the Pyl-45 truncation
mutant was able to bind GARP2, whereas Py46-87 or Py67-87 truncation mutants did not
85
detectibly interact with GARP2 in this assay. We also tested the ability of soluble Py 
fragments to compete with immobilized full-length (His^-Py for binding to GARP2; as 
shown in Fig. 3-2B, two truncation mutants, Pyl-45 or Pyl-66, were as effective as full- 
length Py in blocking binding of GARP2 to immobilized Py, whereas Py truncation 
mutants lacking the N-terminal half of the sequence were ineffective (Fig.3-2B). We 






Fig. 3-2. GARP2 has high-affinity interactions with the N-terminal half of Py.
A. The N-terminal half of Py interacts with GARP2. GST-tagged wild-type or 
truncation mutants of Py (20 nmol) were immobilized on 20 pi glutathione beads 
and incubated with His6-GARP2 (5 nmol). Proteins bound to the beads were 
separated by SDS-PAGE and detected with GARP2 antibody. T: starting sample, 
followed by bound fractions of GST-Pyl-87, Pyl-45, Py46-87, Py67-87-45, and 
control glutathione beads (lacking GST-Py; “C”). B. Competition of immobilized 
Py with exogenous Py or Py truncation mutants. His-Py (20 nM) premixed with 
GARP2 (100 nM) and a 1000-fold excess of either wild-type Py “1-87” or. the 
indicated Py truncation mutant (20 pM) or no exogenous Py (“C”) was pulled down 
using Ni-NTA beads (20 pi). Proteins bound to the beads were analyzed for the 
ability to bind GARP2 using immunoblot detection with the GARP antibody.
The C-terminal region o f GARP2 most effectively reduces the basal activity o f  
non-activated PDE6. Previous work demonstrated that GARP2 isolated from ROS was 
able to reduce the basal catalytic activity of PDE6 (containing endogenous, bound 
GARP2) when exogenous GARP2 was added to ROS membranes containing non­
activated PDE6 (Pentia et al., 2006). We re-evaluated the ability of GARP2 to suppress 
PDE6 basal activity in a reconstituted system containing recombinant GARP2 and
purified GARP2-free PDE6 holoenzyme. As shown in Fig. 3-3. (filled circles), 
exogenous GARP2 suppressed up to 90% of the basal activity of GARP2-ffee PDE6 in a 
dose-dependent manner, with half-maximal suppression requiring a large excess of 
exogenous GARP2 (IC50 = 240 ± 40, n=5). In contrast to the effects of GARP2 on PDE6 
holoenzyme, we observed that incubation of GARP2 with Pap resulted in less than a 10% 
change in catalytic activity at concentrations where the activity o f PDE6 holoenzyme was 
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Fig. 3-3. The C-terminal half of GARP2 is most effective in suppressing the 
basal activity of GARP2-free PDE6. Three different fragments of GARP2 (N- 
terminal half (a.a. 1-150), the central region (a.a. 75-225), and the C-terminal half 
(a.a., 151-299) as well as full-length GARP2 (FL-GARP2) were expressed and 
purified (see Methods). 5 nM GARP2-free PDE6 holoenzyme (obtained by PrBP/8 
solubilization of PDE6; see Experimental Procedures) was incubated for 15 min 
with increasing concentration of GARP2 or GARP2 fragments, and then PDE 
activity measured. The data are representative of at least 3 independent experiments 
for each condition. Similar results were also obtained with GARP2-free PDE6 
obtained by Triton X-100 treatment.
To identify the region of GARP2 responsible for suppressing the basal activity of 
PDE6, we generated three fragments of GARP2 (N-terminal half, C-terminal half, and 
central region) and tested their ability to reduce PDE6 basal activity. As shown in Fig. 3- 
3, the C-terminal half of GARP2 (a.a. 151-299) was similar to full-length GARP2 (299
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a.a.) in its ability to suppress PDE6 basal activity. In contrast, both the N-terminal half 
(a.a. 1-150) and the central region of GARP2 (a.a. 75-225) suppress PDE6 activity to a 
lesser extent (-60% maximal decrease) and require higher concentrations of GARP2 
compared to the C-terminal half of GARP2 (Fig. 3-3). We conclude that the last -75 
amino acids at the C-terminus of GARP2 is most effective in causing suppression of the 
basal catalytic activity of non-activated PDE6, presumably by enhancing the interactions 
of Py with PaP to more effectively block substrate access to the enzyme active site.
GARP2 reduces cGMP binding to PDE6. In addition to regulation by its Py 
subunit, PDE6 is also allosterically regulated by cGMP binding to sites located in the 
regulatory GAFa domains of PDE6 [reviewed in (Cote, 2006)]. Furthermore, the ability 
of Py to alter cGMP binding to the regulatory GAFa domain has been shown to reside 
within the N-terminal half of Py (Zhang et al., 2012), the same region of Py that binds to 
GARP2 with highest affinity (Fig. 3-1B).
We therefore asked whether GARP2 altered the cGMP binding properties of
PDE6 by measuring cGMP binding to PDE6 GAF domains in the presence of increasing
concentrations of GARP2. As shown in Fig. 3-4A, addition of increasing concentrations
of GARP2 resulted in dose-dependent reductions in the amount of cGMP bound to either
PDE6 holoenzyme or Pap. The observation that a large molar excess of added GARP2 is
needed to induce cGMP dissociation (Fig. 3-4A) or to suppress basal catalytic activity
(Fig. 3-3) may arise from the intrinsically disordered structure of GARP2 in solution
(Batra-Safferling et al., 2006) resulting in only a small fraction of the purified GARP2
molecules being in a suitable conformation for high-affinity interactions with PDE6. The
ability of GARP2 to alter cGMP binding to PaP was unexpected based on the failure to
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detect direct binding of GARP2 to PaP in pull-down experiments (Fig. 3-1 A); this 
suggests that GARP2 does directly interact with Pap but its binding affinity is lower 
when the stabilizing influence of Py is absent.
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Fig. 3-4. GARP2 decreases the extent of 
cGMP binding to noncatalytic sites on 
PDE6. A. PDE6 catalytic dimer (PaP; 20 nM) 
or reconstituted holoenzyme (PaPyy; 20 nM) 
was pre-incubated for 15 min with the 
indicated amount of GARP2 and then mixed 
with 1 pM [3H]cGMP for 10 min prior to 
determining the amount of [3H]cGMP bound; 
see Experimental Procedures. Binding data 
compiled from four experiments was 
normalized to the amount bound in the absence 
of GARP2 and fit to a hyperbolic relationship 
(Pap {circles)-. IC50 = 373 ± 104 GARP2/Pap, 
maximum decrease = 88% ± 7%; PDE6 
holoenzyme {triangles)-. IC50 = 264 ± 67 
GARP2/PDE6, maximum decrease = 98% ± 
7%). B. Full-length GARP2 (black) orN- 
terminal (gray), central (ladder), and C- 
terminal (hatched) fragments of GARP2 (all 20 
pM final concentration) were incubated with 
PaP or PaPyy (20 nM) for 15 min, and then the 
extent of binding of 1 pM [3H]cGMP was 
determined. Controls lacking GARP2 (white) 
were also measured, with the extent of binding 
normalized to the amount of cGMP bound to 
PDE6 holoenzyme in the absence of GARP2 
(n=4). One-way ANOVA analysis with Tukey 
test identified statistically significant 
differences between control and all GARP2- 
containing samples (*, p < 0.001), as well 
between certain GARP2-containing samples 
(**, p < 0.001; and ***, p < 0.005).
To determine which region of GARP2 may be responsible for altering cGMP 
binding to PDE6, we repeated cGMP binding experiments using the three recombinant 
GARP2 fragments described above. As show in Fig. 3-4B, cGMP binding to Pap or
PDE6 holoenzyme was reduced following incubation with any of the three GARP2 
fragments (N-terminal, central and C-terminal region of GARP2). The central GARP2 
fragment (a.a. 75-225) reduced cGMP binding to the same extent as full-length GARP2 
(-60% decrease), whereas the N-terminal region (a.a. 1-150) was only half as effective in 
reducing cGMP binding (Fig. 3-4B). We conclude from these experiments that the central 
region of GARP2 is primarily responsible for interacting with PDE6 to destabilize cGMP 
binding to the GAF domains of the catalytic subunits.
GARP2 decreases the efficiency o f  transducin activation o f  PDE6. Previous 
work demonstrated that addition of GARP2 to transducin-activated PDE6 on rod outer 
segment membranes had little effect on the catalytic activity of PDE6 (Pentia et al.,
2006), but did not address whether GARP2 could alter the extent to which transducin can 
activate PDE6. Because GARP2 binding to nonactivated PDE6 alters both catalytic 
activity and cGMP binding properties, we sought to determine the ability of GARP2 to 
alter the mechanism of transducin activation of PDE6. Using a reconstituted system 
consisting of purified, activated transducin a-subunit (Ta*-GTPyS), PDE6 holoenzyme, 
and large unilamellar membranes to enhance transducin activation efficiency; (Melia et 
al., 2000), we tested whether addition of GARP2 prior to transducin could alter the 
efficacy of transducin to activate PDE6. As shown in Fig. 3-5, the presence of GARP2 
was able to reduce by 30% the maximum extent to which PDE6 could be activated; no 
significant change in concentration dependence ( I C 5 0 )  was observed. Similar results were 
obtained regardless of whether the PDE6 holoenzyme preparations contained or lacked 
endogenous, bound GARP2 {data not shown). We conclude from these results that
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GARP2 is able to interfere with the ability of transducin to fully activity PDE6 under 
these experimental conditions.
To probe the underlying mechanism by which GARP2 lowers the efficiency of 
transducin activation of PDE6, we evaluated whether GARP2 was able to directly bind to
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Fig. 3-5. GARP2 reduces the maximum 
extent of transducin activation of PDE6.
PDE6 holoenzyme with endogenous GARP2 
depleted (1 nM) was incubated with large 
unilamellar vesicles in the absence (circles) or 
presence (triangles) of GARP2 (molar ratio 
2000 GARP2 per PDE6). Increasing 
concentrations of Ta*-GTPyS were then added 
and the catalytic activity of PDE6 was 
measured (No GARP2: IC50 = 0.30 ± 0.07 pM, 
Maximal activation = 114 ± 9%; With GARP2: 
IC50 = 0.33 ± 0.03 pM, Maximal activation = 
81 ± 3%). The extent of activation is 
normalized to the PDE activity of fully 
activated Pap. Data represent the mean ± S.D. 
of three experiments. 2000 GARP2 per PDE6 
showed the maximal effects on transducin 
activation in the independent experiments.
transducin. When (His)6-GARP2 was pre-bound to beads and then incubated with 
increasing concentrations of Ta*, no significant interaction of Ta*-GTPyS with GARP2 
was observed (Fig. 3-6). This result suggests that there are no direct, high-affinity 
interactions between GARP2 and Ta*-GTPyS. This led us to hypothesize that the effect 
of GARP2 to suppress the extent to which transducin activates PDE6 may be mediated 
through Py which as we showed above (Fig. 3-IB) is capable of binding both GARP2 and 
Ta*-GTPyS. To test this, we added Py to the GARP2-immobilized beads prior to addition 
of Ta*-GTPyS and found that Py enabled transducin to bind to the beads when Py was 
also present (Fig. 3-6). The simplest explanation of these results is that GARP2 exerts a
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desensitizing effect on transducin activation of PDE6 through direct interactions with Py, 
not with Ta*-GTPyS or Pap.
Fig. 3-6. The interaction between GARP2 and 
transducin is mediated by Py. His-GARP2 (2 nmol) 
was absorbed with 20 pi Ni-NTA beads and 
incubated with Py (0.5 nmol) prior to addition of the 
indicated concentration of Ta*GTPyS (3 pM).
Proteins binding to the beads were analyzed. For 
controls, 3 pM Ta*GTPyS was incubated with Ni- 
NTA beads with His-GARP2 adsorbed (no Py), or to 
Ni-NTA beads lacking both His-GARP2 and Py.
Summary
The experiments reported above identify several regulatory interactions of 
GARP2 with the PDE6 holoenzyme that may underlie some of the physiological 
properties that distinguish rod and cone responsiveness to light stimulation. First, GARP2 
may serve to lower the basal rate of cGMP hydrolysis as a result of direct interactions 
with the inhibitory Py subunit when the PDE6 holoenzyme is in its dark-adapted (i.e., 
nonactivated) state. This regulatory feature may reflect an allosteric change in Py 
conformation upon binding of the C-terminal region of GARP2 (Fig. 3-3) to the N- 
terminal half of Py (Fig. 3-2) that enhances direct blockage of the active site of the 
enzyme (Granovsky et al., 1997). Reducing PDE6 basal activity would serve to reduce 
the component of “dark-noise” attributed to spontaneous activation dark-adapted PDE6 
(Rieke et al., 1996), thereby enhancing the signal-to-noise ratio for detection of single 
photons by rod photoreceptors in their dark-adapted state.
The ability of GARP2 to destabilize cGMP binding to noncatalytic regulatory
sites on the PDE6 catalytic dimer (Fig. 3-4) and to reduce the extent of transducin
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activation (Fig. 3-5) may together serve a different function, namely to reduce the 
fraction of rod PDE6 that is light-activated during bright, continuous illumination that 
causes rod photoresponse saturation. It has been previously shown that when PDE6 lacks 
bound cGMP at its noncatalytic sites, transducin inactivation is accelerated (Arshavsky et 
al., 1991) by a mechanism requiring RGS9-1 (He et al., 1998)] and modulated by Py 
(Arshavsky et al., 1992a). By reducing the extent of cGMP binding to PDE6 catalytic 
subunits, GARP2 may contribute to accelerating transducin GTPase activity that leads to 
PDE6 inactivation. Likewise, the ability of GARP2 binding to PDE6 to reduce the extent 
to which PDE6 is activated by transducin also serves to reduce the efficacy of the 
phototransduction activation pathway. We hypothesize that these two effects of GARP2 
on the phototransduction pathway become relevant only when rod photoreceptors are 
exposed to bright continuous light, and may serve to reduce energy expenditure under 
conditions where cGMP metabolic flux represents a “futile cycle.”
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CHAPTER 4
THE EFFECTS OF ZINC ON PDE6 CATALYTIC ACTIVITY
Abstract
In the PDE superfamily, divalent cations, including zinc, magnesium and 
manganese, are required for the normal catalytic function of most PDEs. A previous 
study has identified the specific conserved residues within the catalytic domain of PDE5 
that contribute to the interaction with magnesium or manganese in supporting catalysis; 
and it also suggested that zinc is the most potent divalent cation supporting catalysis of 
PDE5 (Francis et al., 1994). Although it has been found that the removal of tightly bound 
zinc from PDE6 causes a loss of the activity (He et al., 2000a), the potential regulation of 
zinc content as it related to function of PDE6 is not totally clear.
We hypothesize that zinc is required for the PDE6 catalytic mechanism and 
structural stability of PDE6 and that distinct binding sites where zinc can rapidly 
exchange are likely occupied by magnesium under physiological conditions. In this study, 
different zinc-chelator systems were used to make solutions with defined concentrations 
of free zinc using calculations from the Hyperquad Simulation and Speciation (HySS) 
program. We demonstrated that low concentrations of zinc are able to activate PDE6 
catalytic activity, while high concentrations cause the loss of PDE6 activity.
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Introduction
It is generally accepted that divalent cations are critical to the catalytic function 
and structure of PDEs. Magnesium is used as the divalent cation in PDE activity assays 
(Butcher et al., 1962) and previous studies indicate that the coordination of magnesium in 
enzymes typically requires a site rich in oxygen atoms derived from residues such as Asp, 
Glu, Thr, Ser, and Tyr (Francis et al., 2000). Although it has been widely accepted that 
magnesium is required for PDE catalytic function, other metals including zinc, 
manganese and cobalt were also found to support catalytic activity of most PDEs and in 
certain instances, they are more effective than magnesium (Francis et al., 1994). Several
i <y_i_
studies have reported that the metal-binding sites in several Zn and/or Mn -binding 
enzymes resemble one another by having multiple histidines and acidic residues 
(Christianson, 1997;Egloff et al., 1995). For example, the metal-binding sites in the 
active site of thermolysin uses a nitrogen-rich FDGHXnE motif to coordinate a catalytic 
Zn2+, which can also bind Mn2+ (Matthews et al., 1972).
In previous research, Francis et al. (1994) showed that the catalytic domains of
several PDEs (PDE5, PDE6 and PDE3) contained two metal-binding motifs (HX3HXnE)
arranged in tandem that were separated by 10 amino acids (Francis et al., 1994). These
motifs were similar to the catalytic Zn2+-binding motif found in some metallo-
endopeptidases (Yallee et al., 1990a;Vallee et al., 1990b). The stoichiometry of Zn2+
binding to PDE5 was determined to be three zinc ions per PDE5 monomer (Francis et al.,
1994). Furthermore, single-site mutation of five of the six residues in the two motifs of
PDE5 (His-603, His-607, His-643, His-647, and Glu-672) caused significant loss of
catalytic activity measured in the presence of Mg2+, which suggested that both of these
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metal-binding motifs are required to support normal catalysis in PDEs (Francis et al., 
2000).
Zinc has also been visualized to bind to a metal-ion binding site (Me-1 site) in the 
initial x-ray crystallographic structure of the PDE4 catalytic domain (Xu et al., 2000).
The atomic-level structure of the PDE9 catalytic domain revealed that the Me-1 site is 
occupied by zinc and the Me-2 site is occupied by magnesium (Huai et al., 2004). All 
other x-ray crystallographic structures of isolated PDE catalytic domains are reported to 
have zinc bound, with the exception of PDE3 (Ke et al., 2007) (Scapin et al., 2004). 
Although zinc shows a similar coordination with active site residues in the x-ray crystal 
structures, the measured affinity for zinc varies among these PDEs. The crystal structure 
with zinc binding at Me-1 in the PDE4D catalytic domain was obtained in the presence of 
EDTA, but the zinc can be removed from the PDE 10 isolated catalytic domain after 
incubation with EDTA for 30 min (Wang et al., 2007). However, the incubation of PDE6 
with EDTA for several days is relatively ineffective at removing zinc from PDE6 
holoenzyme, whereas dipicolinic acid (DPA), a higher-affinity zinc chelator, is required 
to remove the tightly bound zinc (He et al., 2000a). The presence of zinc in structures of 
almost all mammalian PDEs along with the biochemical evidence for the tight binding of 
this zinc indicate that it is possible that all mammalian PDEs, except PDE3, may 
constitutively contain zinc in the Me-1 site under physiological conditions. Magnesium 
has been widely considered to occupy the Me-2 binding site, but many PDEs have higher 
affinity for manganese or cobalt than for magnesium in supporting catalytic activity, such 
as in PDE9, in which the activity of manganese is twice that for magnesium (Huai et al., 
2004).
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The Me-1 and Me-2 metal-binding sites in mammalian PDE catalytic domains are 
dissimilar. The coordination of zinc in Me-1 utilizes two invariant histidines and two 
invariant aspartic acid residues and three of these (two histidines and one aspartic acid) 
localize to the “histidine-rich” segment of the PDE catalytic domain sequence. However, 
the other aspartic acid is located near the C terminus of this region. The binding of the 
metal ion in the Me-2 metal-binding site involves one of the aspartic acids, that is also 
found in the Me-1 site along with five water molecules (Ke et al., 2007). Only one amino 
acid in Me-2 directly contacts with the metal ion likely accounting for the lower binding 
affinity for metal at this site. In the study of PDE9, it has been found that the catalytic 
domain of PDE9 can be activated by different combinations of divalent metal ions in Me- 
1 versus Me-2 sites, but the activity and structure of PDE9 differ under various 
combinations of metal ions (Liu et al., 2008). Another study of the structure of PDE4, 
PDE5 and PDE9 found that a hydroxyl ion is the bridging nucleophile for the metals 
between Me-1 and Me-2, with Me-1 believed to be occupied by zinc, and Me-2 occupied 
by either magnesium, manganese, or zinc (Xiong et al., 2006;Liu et al., 2008).
The regulatory significance of metal-ion content in the active sites of PDEs is not 
totally clear. In the core of PDE4, it was found that the phosphorylation of PDE4 by PKA 
increased binding affinity for magnesium (Tollefson et al., 2010). The differing affinities 
for magnesium among different states of the same PDE suggests that changes in divalent 
metal ion concentration within cellular compartments could alter PDE activity and serve 
to regulate PDE activity under physiological conditions.
Zinc plays an important role in the catalytic function of PDEs, but it is unclear
whether it is critical for stabilizing the subdomain structure of the catalytic domain. In a
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study with PDE10A2, the residues His-529, His-563, Asp-564 and Asp-674 were 
identified to directly interact with zinc and contribute to the high-affinity binding of zinc. 
Two mutants (D564A and D674A) were generated that lowered the catalytic activity 
1000-10,000-fold compared to the wild type enzyme with no significant difference in the 
crystal structures (Wang et al., 2006). In the case of PDE5, mutations of His-617 or His- 
653 that directly coordinated with zinc showed the loss of catalytic activity, but the 
activity can be recovered in the presence of a high concentration of manganese (not 
magnesium) (Francis et al., 2000), which suggests that high manganese can fill the 
catalytic role of zinc in the Me-1 site. The removal of metals can also abolish the activity 
of PDE5, but the nucleotide analogs or inhibitors were still able to interact with its 
catalytic pocket (Corbin et al., 2003). The mutation of the downstream aspartic acid in 
PDE5 caused the loss of catalytic activity as well (Turko et al., 1998), which emphasize 
the important role of the downstream aspartic acid in PDE catalytic function.
Previous studies with rod PDE6 have shown that Mg2+ is required for the catalytic 
activity of PDE6 (Pannbacker et al., 1972) and that the concentration of Mg2+ affects the 
apparent Km for cGMP (Srivastava et al., 1995). Rod PDE6 also requires tightly-bound 
zinc for its catalytic activity, with purified PDE6 containing 3-4 g atoms of endogenous 
zinc per mole PDE6 (He et al., 2000a). This is consistent with two tightly bound zincs per 
catalytic subunit. Loss of PDE6 activity occurs when free divalent cations are absent; this 
loss of activity is reversible upon addition of magnesium, manganese, cobalt or zinc.
DPA and EDTA can remove the majority of the tightly-bound zinc at pH 6.0, which 
causes the complete loss of activity of PDE6 even in the presence of magnesium, but the
lost activity could be restored by the addition of zinc (He et al., 2000a).
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The efforts to fully understand the role of divalent cations in the structure, 
catalytic mechanism, and the potential regulation of PDE6 are hampered by difficulties in 
manipulating the identity and stoichiometry of bound metals, as well as controlling the 
free concentration of divalent cations. A better understanding of divalent cations in PDE6 
is important because of evidence that heavy metals may cause loss of visual function of 
the rods and cones of the retina. Therefore, we developed methods to evaluate the role of 
divalent cations in PDE6 activity.
Materials and Methods
Materials—All chelators and other chemicals were obtained from Sigma 
Chemical Co. or from Thermo-Fisher.
Purification o f PDE6 Holoenzyme (Pct-fyy) and PDE6 Catalytic dimer (PaP)— 
Rod PDE6 holoenzyme was purified as described in detail in Chapter 2. The PDE6 
catalytic dimer (PaP) was prepared from the PDE6 holoenzyme by digesting the 
inhibitory Py subunits by limited trypsin proteolysis as described in Chapter 2. The 
purified PaP was buffer-exchanged into 150 mM NaCl in 20 mM HEPES, pH 7.5 
prepared with 50% glycerol and stored at -20 °C. The protein (PDE6 or Pap) was buffer 
exchanged into HEPES buffer to remove the glycerol before use.
Preparation o f Zinc-containing Buffers— First, the metal-free HEPES buffers at
pH 7.4 or pH 7.0 were made by dissolving the powder-formed reagents of the highest
purity in commercially available metal-free distilled water or distilled water purified to
18 megohms of resistance with a Milli-Q reverse osmosis system. The metal-free
solutions were stored in the containers that had been extensively washed with Milli-Q
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water and handled carefully. Second, the free zinc-containing buffers were prepared by 
adding zinc salt to the metal-free solutions based on calculations performed by the HySS 
program (see below). The pH of the zinc-containing buffers was finally adjusted by 
adding HC1 or NaOH solution. All the zinc-containing solutions were stored at 20-25 °C, 
because low temperature sometimes caused precipitation, especially at high zinc 
concentrations.
Determination o f the Activity o f  PDE6 in Zinc Solutions—All solutions used in 
the PDE6 activity assay were prepared in 20 mM HEPES buffer at pH 7.4. Purified PaP 
was buffer exchanged into 150 mM NaCl in 20 mM HEPES, pH 7.4 to remove glycerol. 
Typically, 30 pi free zinc buffer was incubated with 10 ul PDE6 solution in presence of 
0.5 mg/ml bovine y-globulin (BGG) at room temperature for 15 min before adding cGMP. 
The PDE6 concentration was estimated based on the rate of cGMP hydrolysis of trypsin- 
activated PDE6 and the knowledge of the kcat of the enzyme [5600 mol cGMP 
hydrolyzed per mol PaP per s (Mou et al., 1999)].
Data Analysis—The free zinc concentration in this study was calculated by HySS 
program (HySS2009, Ink.) as described by Alderghi. et a/.(Alderighi et al., 1999).
Results and Discussion
Optimize the conditions for measuring PDE6 activity in zinc-containing 
solutions. In order to determine the effects of varying the free zinc concentration on the 
catalytic properties of PDE6, the standard PDE6 activity assay method had to be 
modified.
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In the standard PDE6 activity assay method, 20 mM Tris (pH 7.5) is used to 
buffer the pH, 0.5 mg/ml bovine serum albumin (BSA) is used as a protein carrier or 
“stabilizer”, and 10 mM Mg2+ is added to maximally activate PDE6. As Tris can interact 
with zinc, it is not an ideal buffer. Therefore, HEPES and MOPS buffering systems were 
tested as a replacement for Tris. The maximal activity of PDE6 in HEPES buffer at pH
7.5 (10 mM, 50 mM and 100 mM) or MOPS buffer at pH 7.5 (10 mM, 50 mM and 100 
mM) were compared with the Tris buffering system and the results demonstrated that 
HEPES and MOPS buffers are equally good at buffering pH without altering the maximal 
activity of PDE6. We therefore used one of these Good’s buffers for subsequent 
experiments. Inclusion of BSA in the PDE6 assay buffer serves to reduce the loss of 
PDE6 to due surface effects. For example, in the absence of BSA, the maximal activity of 
PDE6 was reduced greater than 90% compared to including BSA in the assay, supporting 
the idea that a protein carrier or stabilizer is necessary to measure PDE6 activity 
accurately. However, previous studies indicate that BSA can bind zinc with high affinity 
(Ohyoshi et al., 1999). We therefore tested other proteins that do not bind zinc for their 
abilities to stabilize PDE6 in solutions. We tested bovine y-globulin (BGG), ovalbumin, 
lysozyme, and dextran as the candidates to replace BSA. As shown in Fig. 4-1, the 
presence of BGG preserved more than 98% of PDE activity, ovalbumin recovered about 
96% of the activity of the control, and lysozyme or dextran presented about 80% activity 
(all compared to BSA as control). This result shows that BGG can substitute for BSA in 
PDE6 activity assays in studying the effect of zinc on PDE6 activity.
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Fig. 4-1. Characterization of stabilizers 
for PDE6 assay buffer.
The maximal activity of PDE6 was 
measured in the PDE6 assay buffer 
supplemented with different protein 
stabilizers (ovalbumin, lysozyme, BGG 
or dextran). The PDE6 assay buffer 
contained 20 mM Tris, 10 mM MgCb 
with 0.5 mg/ml of each stabilizer at pH
7.5 (dextran at 1 mg/ml). The maximal 
activity measured with 0.5 mg/ml BSA- 
containing assay buffer was used as the 
control.
Evaluate the effects o f  the chelators on PDE6 activity. In order to prepare 
solutions with defined free zinc concentration in solutions, chelators with high affinity to 
zinc must be utilized. The effects of three zinc chelators (NTA, EDTA, and citrate) on 
PDE6 activity were screened. In Fig. 4-2, 10 mM NTA, 10 mM citrate and 10 mM EDTA 
were incubated with PDE6 for 30 min to remove the endogenous divalent cations from
I
PDE6, and then increasing concentrations of Mg were added. The activity of PDE6 was 
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Fig. 4-2. Comparison of the effects 
of different chelators on PDE6 
activity.
The PDE6 activity was measured by 
adding 10 mM of each individual 
chelator to the PDE6 assay buffer for 
30 min and then adding increasing 
concentrations of Mg2+ at pH 7.5. The 
chelators used were NTA {circles), 
citrate {squares) and EDTA 
{triangles). PDE6 activities were 
normalized to the value in the absence 
of chelator.
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chelators were able to block greater than 95% of total PDE6 activity, and in the presence 
of sufficient Mg2+the maximum activity was restored. Since EDTA has a higher affinity 
for Mg2+than NTA or citrate, it required more Mg2+ to fully restore activity.
A time course (from 30 min to 18 hours) of PDE6 exposure to chelator (NTA or 
EDTA) was conducted to determine the loss of PDE6 activity during incubation in the 
absence of free divalent cations. After adding back Mg2+, it was found that short term 
incubation (less than 10 hours) of PDE6 with EDTA or NTA had no effect on the 
recovery of PDE6 activity. Even after an 18 hour incubation 90% of activity could be 
restored (data not shown). These results indicate that the removal of endogenous cations 
of PDE6 causes the loss of catalytic activity, while addition of excess Mg2+ is able to 
restore PDE6 activity.
Use o f different zinc chelators to study the effects o f zinc on the catalysis o f  
PDE6. Previous work suggests that in the absence of other divalent cations, lower 
concentrations of zinc (< 1 pM) are able to activate PDE6, while higher concentrations (> 
1 pM) cause the loss of activity (He et al., 2000a). However, further work is needed to 
better understand the mechanism by which zinc can both activate and inhibit PDE6. In 
this section, several chelators were tested using Hyperquad Simulation and Speciation 
(HySS) program to calculate free zinc concentration in solution containing chelators. 
HySS program is a computer program which is able to provide a speciation diagram 
using the given equilibrium constants ((3) and calculate concentrations of each species in 
the solution system (Alderighi et al., 1999).
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The first chelator examined was nitrilotriacetic acid (NTA) in HEPES buffer at 
pH 7.4; the equilibrium constants of each species in the solution were provided by Dr. 
Roy Planalp and Kyle Burton (UNH Chemistry Department). In this experiment, zinc- 
containing solutions (with and without added Mg24) were prepared based on the 
calculations from the HySS program, and PDE6 incubated with each zinc solution for 15 
min prior to measuring catalytic activity. The results suggest that low concentrations (< 1 
pM) of free Zn2+ activate PDE6 and the highest activity of PDE6 (-90% activity of the 
control) is achieved under the free zinc concentration o f-100 nM. However, 
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Fig. 4-3. PDE6 activity in NTA-Zn HEPES solutions at pH 7.4.
Solutions containing NTA and various concentrations of free Zn2+ in the presence 
or absence of Mg2+ were prepared based on the calculation from HySS program 
(See Methods) and summarized in Tables 4-1 and 4-2. PDE6 (1 nM) was incubated 
with zinc-containing HEPES buffer (pH 7.4) for 15 min before adding cGMP. The 
maximal activity of PDE6 in 10 mM Mg2+ with 0.2 mg/ml BGG in absence of zinc 
or NTA was used as the control. A. PDE6 activity as a function of free Zn2+
^  I
concentrations in absence of Mg . No BGG added {circles) and with 0.5 mg/ml 
BGG added {diamonds). B. The effect of zinc on PDE6 activity in the presence of 1 
mM Mg2+. No BGG added {triangles) and with 0.5 mg/ml BGG added {squares).
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PDE6 (Fig. 4-3A). It was found that the addition of I mM Mg2+ was able to improve the 
basal activity of PDE6, but it did not change the concentration dependence of Zn2+ on 
PDE6 activity (Fig. 4-3B).
In order to further define the range of zinc concentrations that activate PDE6 to 
inhibit PDE6, we lowered the pH to 7.0 to improve our ability to make a set of solutions
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Fig. 4-4. PDE6 activity in NTA-Zn 
HEPES solutions at pH 7.0.
Solutions containing NTA and various 
concentrations of free Zn2+ at pH 7.0 
were prepared based on the calculation 
from HySS program (Table 4-3). PDE6 
(1 nM) was incubated with zinc- 
containing solution in presence of 0.2 
mg/ml BGG in HEPES buffer for 15 min 
before adding cGMP. The maximal 
activity of PDE6 measured in 10 mM 
Mg2+ in the absence of zinc or NTA was 
used as the control.
with free zinc concentration between 100 nM to 1000 nM (Table 4-3). As shown in Fig.
4-4, the pH of the solutions was lowered from 7.4 to 7.0 and we observed a change of
PDE6 activity from activation to inhibition over the range of 200—400 nM free zinc.
These results are in general agreement with the observations at pH 7.4, but with improved
ability to define the free zinc concentrations promoting catalytic activity. Note that the
highest activity of PDE6 in Fig. 4-4 is 68% of the control at pH 7.0, whereas at pH 7.4,
zinc was able to stimulate to 90% of the control.
We also tested the chelator N-(2-acetamido)-iminodiacetic acid (ADA) to prepare
solutions with low free zinc concentration, because ADA has lower affinity for zinc than
NTA. As seen in Fig. 4-5, free Zn2+ activates PDE6 over the range of 50 to 1000 nM free
Zn2+ concentration with no inhibition of activity observed. 1 pM free Zn2+ is the highest
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concentration can be obtained in this ADA-chelating system because of the low solubility 
of the zinc salt under these conditions. Sodium salts including NaCl and NaNC>3 at 
different concentrations were added to increase the ionic strength which may improve the 
solubility of zinc, but no significant change was observed (data not shown). Further work 
is required to optimize the Zn-ADA system.
A third chelator of zinc, histidine (His), was also used. Initially, the effect of 
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Fig. 4-5. Use of ADA to buffer Zn2+.
Solutions with various free zinc 
concentration were made by Kyle 
Burton (Planalp lab) using ADA 
HEPES buffer at pH 7.4 (Table 4-4.). 
PDE6 (1 nM) was incubated for 15 min 
with zinc solution containing 0.2 mg/ml 
BGG. The maximal activity of PDE6 
measured in 10 mM Mg2+ in the absence 
of zinc or ADA is used as the control.
determined that the chelator has no adverse effect on PDE6 activity. In Fig. 4-6, the 
activity curve of PDE6 in Zn-His solutions indicates that this Zn-His system presents
_  24-similar behavior as NTA, in that lower concentrations of free Zn activates PDE6 and 
higher concentrations cause inhibition of PDE6 activity. However, the maximal activity
^  I
is observed at 1000 nM of free Zn using histidine as a chelator compared to ~ 200 nM 
free Zn2+ for the Zn-NTA buffering system. Also noteworthy is the fact that the highest 
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Fig. 4-6. PDE6 activity in His-Zn buffers at pH 7.4.
Zinc solutions with His were prepared as described in Methods (Table 4-5.)- PDE6 
(1 nM) was incubated for 15 min in zinc buffers in the presence of 0.2 mg/ml BGG 
before cGMP was added. The maximal activity of PDE6 measured in 10 mM Mg 
in absence of zinc or His is used as the control. A. Free zinc concentration from 
submicromolar to pM range. B. Free zinc concentration up to mM level.
2+
log
beta IC  (M ) FC (M )
lo g
beta IC (M ) FC (M )
ZnNTA 10.66 Zn 0.001 0.01 ZnNTA 10.66 Zn 0.001 0.01
ZnNTA2 14.24 NTA 0.01 0.01 ZnNTA2 14.24 NTA 0.01 0.01
NTAH 9.73 HEPES 0.1 0.1 MgNTA 5.5 Mg 0.001 0.001
NTAH2 12.22 H pH 7.4 pH 7.4 NTAH 9.73 HEPES 0.1 0.1
NTAH3 14.11 NTAH2 12.22 H pH 7.4 pH 7.4
HEPESH 7.52 NTAH3 14.11
H-l -13.77 HEPESH 7.52
H-l -13.77
Table 4-1. The equilibrium constants of individual species in NTA-chelating 
zinc solutions at pH 7.4 (in absence of Mg2+).
Table 4-2. The equilibrium constants of individual species in NTA-chelating 
zinc solutions at pH 7.4 (in presence of 1 mM Mg24). IC: initial concentration; 
FC: final concentration.
107
log beta IC (M) FC (M)
ZnNTA 10.66 Zn 0.001 0.01
ZnNTA2 14.24 NTA 0.01 0.01 Table 4-3. The equilibrium
constants of individual species
NTAH 9.73 HEPES 0.1 0.1 in NTA-chelating zinc solutions




log beta IC (M) FC (M)
ZnADA 7.1 Zn 0.001 0.005 Table 4-4. The equilibrium
HEPESH 7.52 ADA 0.005 0.005 constants of individual species
ADAH 6.67 HEPES 0.1 0.1
in ADA-chelating zinc solutions
at pH 7.4.
ADAH2 8.89 pH 7.4 7.4
H-l -13.77
log beta IC (M) FC (M)
ZnHisH 1137 Zn 0.0005 0.008
ZnHis2 12.04 His 0.01 0.01
ZnHis 6.51 HEPES 0.1 0.1
Table 4-5. The equilibrium
constants of individual species
ZnHis2H2 23.51 pH 7.0 7.0 in His-chelating zinc solutions at
ZnHis2H 17.84 pH 7.4.
HisH 9.1
HisH2 15.15





The conditions for the PDE6 activity assay were optimized in this study in order 
to study the effects of zinc on the catalytic mechanism of PDE6. The conditions include 
using HEPES to buffer the pH instead of Tris, and replacing BSA with BGG as the 
protein carrier for stabilizing PDE6. Using these optimized conditions, the effects of zinc 
on PDE6 activity was determined using three different chelators including NTA, ADA 
and histidine. Although more work is needed to fully characterize divalent cation 
requirements for PDE6 activity, our preliminary results suggest that sub-micromolar 
concentrations of free Zn2+ activate PDE6 while higher concentrations are inhibitory. In 
one instance, inclusion of Mg2+ with Zn2+ did not shift the activation and inhibition 
profile. In the future, independent methods for validating the free zinc concentration need
to be developed. We hypothesize that the binding of Zn to the high-affinity binding site
1
is necessary for the normal catalytic function of PDE6. However, Zn at a high 
concentration may exchange Mg2+ from the low-affinity Zn2+ binding site and cause an 
inhibitory effect on PDE6 activity.
109
CONCLUSIONS
In order to better understand the regulatory mechanism of photoreceptor 
phosphodiesterase (PDE6) during dark- and light-adaptation, the interaction between 
PDE6 and its high-affinity binding partner, glutamic acid-rich protein (GARP2) was 
determined in this study and the regulatory function of GARP2 on PDE6 in 
phototransduction was also examined here'
First, we optimized the conditions of the immunological methods with different 
primary antibodies to characterize and localize GARP2 since GARP2 lacks enzymatic 
activity and presents abnormal migration on SDS-PAGE. We also improved several 
approaches to isolate PDE6 from its high-affinity bound GARP2 from rod outer segment 
membranes to achieve PDE6 lacking GARP2 as well as PDE6-free GARP2 used in 
subsequent study. In addition, we generated, expressed and purified 6xHis and GST 
tagged full-length bovine GARP2, as well as three fragments of GARP2 with 6xHis tag 
to overcome the drawbacks of native GARP2. The quantity and purity of recombinant 
GARP2 were greatly improved compared with native GARP2, and the biochemical and 
biophysical studies on recombinant GARP2 suggests that it behaves similarly to native 
GARP2 in its ability to suppress of the basal activity of PDE6, its high-affinity 
interaction with PDE6, as well as its hydrodynamic properties. Using recombinant 
GARP2 has allowed us to advance our knowledge of the regulatory functions of GARP2 
on PDE6 activation and inactivation.
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The* primary objective of this thesis was to evaluate the high-affinity interactions 
between GARP2 and PDE6, and examine the regulatory functions of GARP2 on PDE6. 
Using immunoprecipitation and pull-down assays, we identified the inhibitory y subunit 
as the primary interacting subunit with GARP2. Furthermore, we also found that the N- 
terminal region of Py is the major interacting sites between GARP2 and Py. We further 
discovered that the C-terminal portion of GARP2 is the most effective region to suppress 
the basal activity of PDE6. In addition to studying the effects of GARP2 on PDE6 
catalytic properties, we also demonstrated that the binding of GARP2 reduces cGMP 
binding to the noncatalytic binding sites on PDE6 GAF domains. This effect may be 
related to the ability of GARP2 to decrease the extent to which transducin activates PDE6 
(through its interaction with Py). Overall, these results indicate that GARP2 alters not 
only the catalytic but also the allosteric properties of PDE6 to regulate PDE6 activity and 
lifetime through multiple interacting sites with the PDE6 holoenzyme. We conclude that 
GARP2 may play an important role in lowering the level of “dark noise” by suppressing 
the basal activity of PDE6, as well as reducing cGMP metabolic flux. As a consequence 
of its effects on cGMP binding and transducin activation, GARP2 may play a second, 
distinct role in regulating PDE6 lifetime during bright light conditions where the rod 
photoresponse is saturated.
We also investigated the effects of zinc on the catalytic mechanism and structural 
stability of PDE6. In this research, we utilized several different zinc-chelator systems to 
prepare the solutions with defined concentrations of free zinc using calculations from the 
Hyperquad Simulation and Speciation (HySS) program. We demonstrated that low
111
concentrations of zinc (100~1000 nM) are able to activate PDE6 catalytic activity, while 
high concentrations (> 1 fiM) cause the loss of PDE6 activity.
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Appendix I. List of vertebrate CNGB1 and GARP sequences
Species Accession Number Lucos Number Amino acid Number
Human NM 001135639.1 NP 001129111 299
Bovine NM 001135641.1 NP 001129113 299
Mouse BC046523 AAH46523 310
Mouse NM 145601.1 NP 663576 326
Cod EN SGMOT00000014055 Ensembl 458
Stickleback ENSGACP00000023240 Ensembl 458
Dolphin XM 004319364.1 XP 004319412 478
Fugu ENSTRUP00000023842 Ensembl 499
Platypus ENSO ANPOOOOOO19193 Ensembl 531
Bovine NM 001135640.1 NP 001129112 590
Finch ENSTGUP00000004975 Ensembl 596
Tetraodon EN STNIP00000006913 Ensembl 696
Zebrafish EN SD ARP00000089356 Ensembl 708
Tilapia EN SONIP00000004197 Ensembl 730
Turtle EN SPSIP00000004213 Ensembl 839
Frog ENSXETP00000030125 Ensembl 846
Dog ENSCAFPOOOOOO12647 Ensembl 866
Opossum ENSMODP00000019542 Ensembl 866
Armadillo XM 004482945.1 XP 004483002 872
Pig EN S S SCP00000003030 Ensembl 1099
Squirrel
monkey XM 003943523.1 XP 003943572 1164
Shrew XM 004600938.1 XP 004600995 1179
Whale XM 004265068.1 XP 004265116 1189
Gorilla ENSGGOP00000016722 Ensembl 1190
Megabat ENSPVAP00000004359 Ensembl 1204
Pika XM 004584134.1 XP 004584191 1213
Monkey XM 001100587.2 XP 001100587 1218
Galago XM 003792621.1 XP 003792669 1233
Marmoset XM 003735314.1 XP 003735362 1237
Rabbit EN SOCUP00000009093 Ensembl 1237
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Guinea pig ENSCPOPOOOOOO12882 Ensembl 1241
Baboon XM 003916957.1 XP 003917006 1247
Human NM 001297.4 NP 001288 1251
Panda XM 002912291.1 XP 002912337 1252
Bonobo XM 003823719.1 XP 003823767 1256
Hedgehog XM 004704871.1 XP 004704928 1262
Horse XM 001494231.3 XP 001494281 1272
Manatee XM 004371664.1 XP 004371721 1281
Rhinoceros XM 004431848.1 XP 004431905 1293
Mole XM 004799562.1 XP 004799619 1295
Chicken XM 001231877.3 XP 001231878 1303
Squirrel ENSSTOP00000006724 Ensembl 1322
Chimpanzee XM 510998.4 XP 510998 1324
Mouse HOI 16386.1 ADM45272 1325
Sheep XM 004023493.1 XP 004023542 1329
Rat NM 031809.1 NP 113997 1339
Jerboa XM 004663445.1 XP 004663502 1342
Walrus XM 004395831.1 XP 004395888 1352
Degu XM 004626047.1 XP 004626104 1357
Cow NM 181019.2 NP 851362 1394
Orangutan XM 002826489.2 XP 002826535 1411
Cat XM 003998101.1 XP 003998150 1450
Ferret XM 004690242.1 XP 004690299 1491
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Appendix n. Multiple sequence alignment of the N-terminal region of
CNGB1
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